Document:

EX-10.23

 Exhibit 10.23 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS
THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
 MERCK PARTNERED PRODUCT RESEARCH SERVICES AND LICENSE AGREEMENT

 THIS MERCK PARTNERED PRODUCT RESEARCH
SERVICES AND LICENSE AGREEMENT (the “Agreement”) is made as of January 27, 2021 (the “Effective Date”), by and
between ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Artiva”), having an address of 4747 Executive Drive, Suite 1150, San Diego, CA 92121, and
GREEN CROSS LABCELL CORPORATION, a Korean corporation (“GCLC”), with its principal place of business at 107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si,
Gyeonggi-do, 446-850, 16924, Republic of Korea. 

RECITALS 

WHEREAS, Artiva and GCLC are parties to that certain Option and License Agreement dated September 4, 2019, as
amended on June 23, 2020 (as may be amended in accordance with its terms, the “Master Agreement”); 

WHEREAS, Artiva and Merck Sharp & Dohme Corp. (“Merck”) are entering into
that certain Collaboration and License Agreement (attached hereto as Exhibit C, as may be amended in accordance with its terms, the “Collaboration Agreement”), for the development and commercialization of
Merck Products targeting up to three Collaboration Targets (as defined below); 
 WHEREAS, in order to facilitate the
Collaboration Agreement, with respect to the Merck Products only, Artiva and GCLC desire to provide for certain modifications to the terms of the license granted by GCLC to Artiva under the Master Agreement and to modify the payments to be made by
Artiva to GCLC solely with respect to the Merck Products as set forth in this Agreement during the term of this Agreement; 

WHEREAS, GCLC has personnel, expertise and facilities suitable for performing preclinical research and development
services on behalf of third parties; 
 WHEREAS, Artiva desires to engage GCLC to provide mutually agreed research
services in support of the research and development of the Merck Products, to be overseen by the JRCC (as defined in the Collaboration Agreement), in accordance with the responsibilities and authority of the JRCC set forth in the Collaboration
Agreement; 
 WHEREAS, Artiva and GCLC desire to enter into this Agreement to govern the relationship between the
parties with respect to the Merck Products and the terms and conditions that would apply to the services, license and other matters described above. 
  

 AGREEMENT 

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and premises contained in this
Agreement, the receipt and sufficiency of which are hereby expressly acknowledged, the parties hereto agree as follows: 
  

	1.	 DEFINITIONS. 

Capitalized terms used in this Agreement (other than the headings of the Sections or Articles) have the following meanings set forth in this Article 1, or, if
not listed in this Article 1, the meanings as designated in the text of this Agreement. Capitalized terms used in this Agreement but not otherwise defined herein shall have such meanings ascribed to them in the Master Agreement. 

1.1 “Affiliate” means, with respect to a particular party, a person, corporation,
partnership, or other entity that controls, is controlled by or is under common control with such party. For the purposes of the definition in this Section 1.1, the word “control” (including, with correlative meaning, the terms
“controlled by” or “under the common control with”) means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such
entity, whether by the ownership of at least fifty percent (50%) of the voting stock of such entity, or by contract or otherwise. 

1.2 “Antibody Binder” shall mean the antigen recognition domains of any and all proteins, protein fragments,
or peptides that contain a heavy chain complementarity determining region 3 (CDR3) from an antibody directed to a Collaboration Target. For clarity, the proteins, protein fragments, or peptides as used in the foregoing sentence shall include full
length antibodies, nanobodies, antigen-binding fragments (Fabs), and single-chain variable domain fragments (scFvs). 

1.3 “Arbitrators” shall have the meaning set forth in Section 11.5. 

1.4 “Arising GCLC Core IP” shall mean any Arising Intellectual Property relating to methods and tools for
culturing or engineering NK Cells, NK Cells produced and/or reduced to practice by such methods (including NK Cells containing CARs and NK Cells with other receptor or marker modifications) to the extent they do not include an antigen recognition
domain that targets a Collaboration Target, or the use or manufacture thereof, NK Cell manufacturing and production methods or cryoformulation technologies. For clarity, Patents within Arising GCLC Core IP shall not recite (a) a Collaboration
Candidate or (b) a CAR-NK Cell expressing a CAR containing an Antibody Binder directed to a Collaboration Target or a CAR structure containing an Antibody Binder directed to a Collaboration Target; any
such Patents shall be Arising Merck Product IP.      

  
 2. 

 1.5 “Arising Intellectual Property” shall mean any
invention conceived or reduced to practice in performance of the Services under this Agreement, or in the Work Product generated under this Agreement by GCLC’s employees, agents, consultants, subcontractors or other representatives, either
solely or jointly with employees, agents, consultants or other representatives of Artiva and/or Merck, including all patent and other intellectual property rights therein. 

1.6 “Arising Merck Product IP” shall mean such Arising Intellectual Property that (a) is conceived and/or
reduced to practice in the course of, or as a result of, performance of the Research and CMC Plan and associated Work Orders; and (b) relates specifically to any of the following: 

(i) a Collaboration Candidate, CAR-NK Cell expressing a CAR containing an Antibody Binder directed to a
Collaboration Target, or a CAR structure containing an Antibody Binder directed to a Collaboration Target, including compositions, methods of use or processes of manufacture that are specific to the manufacture or use of any such Collaboration
Candidate, CAR-NK Cell, or CAR structure, as applicable; 
 (ii) Antibody Binders (including
compositions, methods of use, or processes of manufacture of an Antibody Binder); or 
 (iii) any other Arising Intellectual Property that is
not Arising GCLC Core IP. 
 For clarity, any Patents within Arising Intellectual Property that recite a Collaboration Candidate, a CAR-NK Cell expressing a CAR containing an Antibody Binder directed to a Collaboration Target, a CAR structure containing an Antibody Binder directed to a Collaboration Target, or an Antibody Binder directed to a
Collaboration Target shall be considered Arising Merck Product IP. 
 1.7
“CAR-NK Cell” shall mean a NK cell expressing a Chimeric Antigen Receptor. 

1.8 “C.F.R.” shall mean the Code of Federal Regulations, as amended. 

1.9 “Chimeric Antigen Receptor” or “CAR” shall mean an engineered single-chain antigen receptor composed of four distinct modules comprising: (i) an antigen recognition domain (ii) an extracellular hinge region, (iii) a transmembrane domain, and (iv) an
intracellular signaling domain, including one or more chimeric domains from co-stimulatory proteins. 

1.10 “Claim” shall have the meaning set forth in Section 11.5. 

1.11 “Collaboration Candidate” shall mean any CAR-NK Cell that
(i) is generated by or on behalf of Artiva and/or Merck under the Collaboration Agreement, (ii) targets a Collaboration Target, and (iii) has been designated as a lead or backup candidate under the Research and CMC Plan. 

  
 3. 

 1.12 “Collaboration Targets” shall mean any target
designated as a Collaboration Target (as such term is defined in the Collaboration Agreement) in the Collaboration Agreement and approved by GCLC, including the potential Collaboration Targets set forth in Exhibit A. Such approval may only be
withheld in the event of a Conflict, which shall mean with respect to any solid tumor associated antigen that is proposed as a Collaboration Target by Merck, that as of the date of such proposal by Merck, such solid tumor associated antigen is: (i)
[***], (ii) [***] or (iii) [***]. 
 1.13 “Confidential Information” shall have the meaning set forth in
Section 7.1. 
 1.14 “GCLC Background IP” shall mean any intellectual property owned or controlled by
GCLC as of the Effective Date of this Agreement relating to methods and tools for culturing or engineering NK Cells, NK Cells produced and/or reduced to practice by such methods (including NK Cells containing CARs and NK Cells with other receptor or
marker modifications), or the use or manufacture thereof, NK Cell manufacturing and production methods or cryoformulation technologies; or any such intellectual property invented or acquired by GCLC during the Term independent of this Agreement,
which GCLC makes available to Artiva for purposes of performing the Services under this Agreement. For clarity, such GCLC Background IP shall include all patents and patent applications listed in Exhibit E and any and all divisionals,
continuations, continuations-in-part, reissues, renewals, substitutions, registrations, re-examinations, revalidations,
extensions, supplementary protection certificates, and the like of any such patents and patent applications, and foreign equivalents of any of the foregoing. 

1.15 “GCLC Territory” shall mean Asia, Australia, and New Zealand. For clarity, Asia includes China
(including Hong Kong and Macau), Japan, Mongolia, North Korea, South Korea, Taiwan, Brunei Darussalam, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, Timor-Leste, Vietnam, Afghanistan, Bangladesh, Bhutan, India,
Maldives, Nepal, Pakistan and Sri Lanka. 
 1.16 “ICDR” shall have the meaning set forth in
Section 11.5. 
 1.17 “Materials” shall have the meaning set forth in Section 3.6. 

1.18 “Merck Field” shall mean any and all uses. 

1.19 “Merck Product” shall mean any pharmaceutical or biological product or therapy, in any form, formulation
or delivery mode and including any permitted modifications thereof, which contains or comprises a Collaboration Candidate or a CAR-NK Cell or CAR structure generated under this Agreement that is directed to
the same Collaboration Target as the Collaboration Candidate, (i) for sale by prescription, over the counter or any other method; or (ii) for administration to human patients in a clinical trial; and in the case of either (i) or (ii),
for any and all uses in the Merck Field, including any combination product. 

  
 4. 

 1.20 “Merck Product License” shall have the meaning set
forth in Section 2.2(a). 
 1.21 “Merck Product Revenues” shall have the meaning set forth in
Section 2.3(a). 
 1.22 “Merck Product Term” shall mean the term of the Collaboration Agreement. 

1.23 “Merck Territory” shall mean all the countries in the world. 

1.24 “Project” shall mean a set of specific research or development activities with respect to a Merck Product
to be performed, or other services to be provided, by GCLC under one or more Work Orders under this Agreement. 
 1.25
“Protocol” shall mean a written protocol, proposed by Artiva and approved in writing by GCLC, detailing the instructions for conducting a particular Project (or portion thereof). Each Protocol shall be attached to the applicable Work
Order and incorporated therein. A Protocol may only be amended upon mutual agreement of the parties, which such amendment shall be attached to the original Protocol and incorporated therein. 

1.26 “Regulatory Authority” shall mean any U.S. or foreign regulatory or governmental authority, such as the
U.S. Food and Drug Administration, the European Medicines Agency, or any successor agency thereto. 
 1.27 “Research
and CMC Plan” shall mean the research, preclinical development and CMC plan agreed to for each Merck Product under the Collaboration Agreement, and attached as an exhibit to this Agreement. 

1.28 “Results” shall have the meaning set forth in Section 3.5. 

1.29 “Rules” shall have the meaning set forth in Section 11.5. 

1.30 “Services” shall mean the particular tasks to be performed by GCLC for a given Project pursuant to this
Agreement, as more fully set forth in the applicable Work Order. 
 1.31 “U.S.C.” shall mean the United
States Code, as amended. 
 1.32 “Work Order” shall mean that document for a given Project under which GCLC
agrees to perform Services for such Project pursuant to this Agreement. 

  
 5. 

 1.33 “Work Product” shall mean any and all results
(including Results) and products (interim and/or final) of the Services performed by GCLC, whether tangible or intangible, including, without limitation, each and every invention, discovery, design, drawing, protocol, process, technique, formula,
trade secret, device, compound, substance, material, pharmaceutical, method, software program (including, without limitation, object code, source code, flow charts, algorithms and related documentation), listing, routine, manual and specification,
whether or not patentable or copyrightable, that are made, developed, perfected, designed, conceived or first reduced to practice by GCLC, either solely or jointly with others, in the course and as a result of performing the Services; but excluding
GCLC Background Technology. 
  

	2.	 LICENSE TERMS FOR MERCK PRODUCTS.

 2.1 Overview. Notwithstanding anything to the contrary contained in this Agreement,
all Arising Merck Product IP shall be governed exclusively by the terms of this Agreement. The Master Agreement sets forth a license by GCLC to Artiva with respect to Licensed Products under the GCLC Core Technology in the Territory and the economic
and other terms of such license. Artiva and GCLC agree that, during the Merck Product Term with respect to the GCLC Background IP and Arising GCLC Core IP only, the terms of this Agreement shall modify the licenses and rights granted by GCLC
to Artiva solely with respect to the Merck Products under the Master Agreement and the economic and other terms of such licenses and rights as expressly set forth herein. Immediately at the end of the Merck Product Term, all rights, licenses,
obligations, terms and conditions applicable to any Licensed Product that was a Merck Product under this Agreement shall automatically, without further action by any party, again be subject to all rights, licenses, obligations, terms and conditions
applicable to such Licensed Product under the Master Agreement and the terms of this Agreement shall no longer apply to such Licensed Product; provided that, for the avoidance of doubt, any Merck Product for which the Royalty Term (as such term is
defined in the Collaboration Agreement) in a given country has expired pursuant to the terms of the Collaboration Agreement shall not be subject to any further royalties in respect of sales of such Licensed Product in such country, including Core IP
Royalties, and the Merck Product License in such country shall be fully paid-up, perpetual and royalty-free and shall survive any expiration or termination of this Agreement or the Master Agreement. 

2.2 License Grant. 

(a) Subject to the terms and conditions of this Agreement, GCLC hereby grants to Artiva, the following licenses during the Merck Product
Term (the “Merck Product License”): 
 (i) an exclusive license (even as to GCLC)
in the Merck Field and the Merck Territory under GCLC’s interest in Arising Merck Product IP, with the right to grant and authorize sublicenses, including without limitation: (x) to research, develop, to make, have made, use, import, offer
to sell and sell Merck Products and (y) to research, develop, make, have made, use, import, offer to sell and sell any invention claimed in or covered by Arising Merck Product IP; 

  
 6. 

 (ii) an exclusive license (even as to GCLC) in the Merck Territory and in the Merck Field
under (i) GCLC Background IP and (ii) GCLC’s interest in Arising GCLC Core IP, with the right to grant and authorize sublicenses, to research, develop, make, have made, use, import, offer to sell and sell Merck Products; and 

(iii) Notwithstanding the scope of the licenses granted to Artiva under Sections 2.2(a)(i) and 2.2(a)(ii), GCLC shall retain the rights under
GCLC Background IP and Arising GCLC Core IP in the GCLC Territory for all other purposes except for the license granted in 2.2(a)(ii). 

(b) As a Licensed Product, all terms and conditions of the Master Agreement shall apply to the Merck Products, except that, solely as
applied to the Merck Products and no other Licensed Products: 
 (i) references to the defined term “Territory” in the Master
Agreement shall be deemed to refer to the Merck Territory, and references to the defined term “Field” in the Master Agreement shall be deemed to refer to the Merck Field; 

(ii) references to the defined term “Core License” in the Master Agreement shall be deemed to refer to the Merck Product License;

 (iii) the Core IP Royalties shall not be payable with respect to the Merck Products; and 

(iv) for the avoidance of doubt, the Merck Products are not a Selected Product nor an Exercised Selected Product under the Master Agreement.

 (c) For clarity, any of the modifications in clauses (b)(i)-(iv) do not apply to any other Licensed Product that is not a Merck
Product. 
 2.3 Merck Product Revenues 

(a) During the Merck Product Term with respect to the Merck Products only, in lieu of the Core IP Royalties, Artiva shall pay GCLC a
percentage of Merck Product Revenues received by Artiva from Merck as follows (such payments, “Merck Product Payments”): (i) one hundred percent (100%) of Merck Product Revenues that are milestone payments or
royalties solely relating to Merck Products in Asia, Australia and New Zealand, and (ii) fifty percent (50%) of all other Merck Product Revenues. “Merck Product Revenues” means royalties, upfront payments,
license fees, regulatory or sales milestone payments and any other payments received by Artiva from Merck, including, without limitation to, the potential Merck Product Revenues described in Exhibit D, [***]. 

(b) Within [***] ([***]) days following Artiva’s receipt of Merck Product Revenues, Artiva shall provide GCLC with a report
containing the following information for the applicable payment: (i) the amount of Merck Product Revenues received, and (ii) a calculation of the Merck Product Payment due to GCLC. Concurrent with the delivery of the applicable report,
Artiva shall pay the payment due to GCLC pursuant to Section 2.3(a). 

  
 7. 

 2.4 Exclusive Efforts. During [***], each of GCLC and Artiva shall work exclusively
with the other party and with Merck with respect to [***], and shall not (and shall cause its Affiliates not to), directly or indirectly and alone or with Affiliates or Third Parties, research, develop, make, have made, use, sell, have sold or
import any [***], except pursuant to, and subject to the terms and conditions of, this Agreement. 
  

	3.	 RESEARCH SERVICES. 

3.1 Scope of Agreement. Under this Agreement, GCLC will perform certain activities and provide specific Services
relating to Merck Products directed against up to three Collaboration Targets, as set forth in the applicable Research and CMC Plan for each Merck Product. The Research and CMC Plan for the initial Merck Product is attached as Exhibit B-1. The parties agree that this Agreement shall be amended to add Exhibits B-2 and B-3 to reflect such Research and CMC
Plans as may be agreed to for two additional Merck Products under the Collaboration Agreement. In partial consideration for its receipt of the Merck Product Payments under Section 2.3, GCLC acknowledges its responsibility to perform the
activities assigned to GCLC under the Research and CMC Plans, and agrees that its failure to perform such activities under a Research and CMC Plan or associated Projects and Work Orders under this Agreement, would constitute a material breach of
this Agreement. Provided that, GCLC shall not be held liable for any delays or failure to perform if such delay or failure is caused by Artiva, its Affiliates and/or any third party appointed by Artiva participating in any part of the Research and
CMC Plan, associated Projects or Work Orders under this Agreement. 
 3.2 Performance of Services. As a master
form of contract, this Agreement allows the parties to contract, with respect to each Research and CMC Plan, for multiple Projects through the issuance of multiple Work Orders, without having to re-negotiate
the basic terms and conditions contained herein. Each Work Order shall become effective only upon signature by both parties. Each Work Order shall set forth, upon terms mutually agreeable to the parties, the specific Services to be performed by
GCLC, the timeline and schedule for the performance of such Services, and the compensation to be paid by Artiva to GCLC for the provision of such Services, as well as any other relevant terms and conditions. Any Protocol applicable to a particular
Project shall be attached to, and is thereby incorporated by reference in, the corresponding Work Order. If a Project includes the development of specific Work Product, the specifications of such Work Product shall be set forth in the relevant Work
Order. If a Project involves any study the results of which are expected or intended to be submitted to any Regulatory Authority, the relevant Work Order shall specify: (a) any particular laws, rules, regulations, guidelines and standards
(e.g., current good laboratory practices) of any Regulatory Authority or other body that GCLC agrees to comply with in performing such Project; and (b) any obligations of Artiva or Merck, as sponsor of an IND application and otherwise,
pursuant to 21 C.F.R. § 312.50 or other applicable laws, rules and regulations in connection with such Project that GCLC agrees to assume from Artiva. There shall be no minimum or maximum 

  
 8. 

 
number of Work Orders to be entered into under this Agreement or in connection with a specific Project. Each Work Order shall be subject to acceptance by GCLC and all of the terms and conditions
of this Agreement, in addition to the specific details set forth in the Work Order. To the extent any terms or provisions of a Work Order conflict with the terms and provisions of this Agreement, the terms and provisions of this Agreement shall
control, except to the extent such Work Order specifically states the parties’ intent that such Work Order control with respect to a particular matter. Any changes to a Work Order shall be in writing, executed by each party, attached to the
original Work Order and incorporated therein. 
 3.3 Compliance with Work Orders and Law. GCLC agrees to perform the
Services set forth in each Work Order in a competent and professional manner and in strict accordance with the terms and conditions contained in this Agreement, the applicable Protocol(s) and such Work Order. Both parties hereto shall perform the
obligations set forth herein in conformance with all applicable laws, rules and regulations, including, if applicable, current good laboratory practices. If government regulatory requirements applicable to any Work Order are changed, then Artiva
shall notify GCLC of all such changed requirements, and GCLC shall comply with the new requirements. If compliance with new regulatory requirements necessitates a change in a Work Order, Artiva shall amend the Work Order and obtain GCLC’s
written consent to such change prior to implementation. During the Merck Product Term, all employees and subcontractors of a party or its Affiliates performing research, development, commercialization or other activities contemplated hereunder on
behalf of such party or its Affiliates shall be obligated to undertake in writing obligations of ownership of Information, discoveries and inventions which are the same as those undertaken by the parties pursuant to Section 6. 

3.4 Subcontractors. Save for subcontracting to its Affiliates, GCLC may not subcontract any of the Services under a Work
Order without Artiva’s prior written consent, except to the extent expressly permitted by such Work Order. GCLC shall at all times be responsible for the compliance of its permitted subcontractors with the terms and conditions of this
Agreement. 
 3.5 Results. GCLC shall record, or cause to be recorded, all data generated by GCLC or its
employees, agents, consultants, Artiva-approved subcontractors or other representatives in the course of conducting a Project, whether in written, graphic or electronic form or contained in any computer database or in any computer readable form
(collectively, the “Results”), in a timely, accurate and complete manner. GCLC and any approved subcontractors shall utilize such electronic notebook system as may be provided by Artiva. To the
extent not contained in the electronic notebooks, copies of all Results collected shall be scanned to electronic files and delivered to Artiva by GCLC in a timely manner throughout the performance of the Project and in accordance with the applicable
Work Order and in compliance with any applicable Protocols provided by Artiva. For purposes of clarification, this section shall apply to each Project individually. 

  
 9. 

 3.6 Materials. Artiva shall either reimburse for, or provide
at no cost to GCLC, the applicable materials necessary for performance of a Project as specified in the applicable Work Order, which may include, without limitation, Merck Products (collectively,
“Materials”), in amounts sufficient for the conduct of the Project. All such Materials shall remain the sole property of Artiva. GCLC shall use the Materials solely in furtherance of the Services
in accordance with this Agreement and Work Orders, shall not deliver the Materials to, or use the Materials for the benefit of, any third party without the prior written consent of Artiva, and shall use the Materials in compliance with all
applicable laws, rules and regulations. The Materials supplied under this Agreement must be used with prudence and appropriate caution in any experimental work because not all of their characteristics may be known. Except as expressly set forth
herein, THE MATERIALS ARE PROVIDED “AS IS” AND WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY PARTICULAR PURPOSE OR ANY WARRANTY THAT
THE USE OF THE MATERIALS WILL NOT INFRINGE OR VIOLATE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF ANY THIRD PARTY. 
  

	4.	 PAYMENT AND BUDGET. 

4.1 Estimated Budget; Accounting. Except to the extent a Work Order provides for GCLC to perform Services on a fixed-fee basis, each Work Order shall contain an estimated budget for the performance of the Work Order, as well as additional terms and conditions relating to such estimated budget, and GCLC shall provide to
Artiva, at intervals stated in each Work Order, an accounting of costs incurred and accrued to date for Services under the applicable Project. 

4.2 Invoices; Payment. Unless otherwise agreed by the parties in writing, GCLC shall provide to Artiva for each Work
Order one or more separate invoices (to be delivered at intervals specified in such Work Order), such invoice summarizing the Services performed during that period of time under that Work Order and the costs therefor. Artiva shall pay each invoice
within [***] days of receipt thereof, in accordance with the applicable schedule of payments specified in such Work Order. Artiva shall not be obligated to pay any amounts in excess of the budget or other payments specified in a Work Order that
have not been approved in writing by Artiva in advance. 

  
 10. 

 4.3 Income Tax Withholding. Except as otherwise provided
herein, GCLC will pay any and all taxes levied on GCLC on account of any payments made to it under this Agreement. GCLC shall be responsible for any transfer, documentary, sales use, stamp, registration, value added or other similar tax
(“Transfer Tax”) that is imposed with respect to the payments or the related transfer of rights or other property pursuant to the terms of this Agreement. If any taxes are required to be withheld by Artiva from any payment made to
GCLC under this Agreement (“Withholding Taxes”), Artiva shall (a) deduct such Withholding Taxes from the payment made to GCLC, (b) timely pay the Withholding Taxes to the proper taxing authority, and (c) send proof of
payment to GCLC and certify its receipt by the taxing authority within [***] ([***]) days following such payment and all such Withholding Taxes shall be treated for all purposes under this Agreement as having been paid to GCLC. To extent Artiva
fails to withhold Withholding Taxes from, or apply and pay Transfer Taxes with respect to, any payment to GCLC and it is determined that Artiva should have withheld Withholding Taxes or applied and paid Transfer Taxes, GCLC agrees to indemnify
and/or reimburse Artiva for any Withholding Taxes or Transfer Taxes. 
 4.4 Tax Documentation. GCLC has provided a
properly completed and duly executed IRS Form W-8BEN-E to Artiva. Prior to the receipt of any payment under this Agreement, GCLC (and any other recipient of payments by
Artiva under this Agreement) shall, to the extent it is legally permitted to, provide to Artiva, at the time or times reasonably requested by Artiva or as required by applicable Law, such properly completed and duly executed IRS Forms W-8 or W-9 claiming the benefits of an applicable tax treaty in the case of IRS Form W-8BEN-E.
Such tax forms will, if applicable and legally permissible, claim the benefits of an applicable tax treaty to permit payments made under this Agreement to be made without, or at a reduced rate of, withholding for taxes. 

4.5 Records Audit. Except to the extent a Work Order provides for GCLC to perform Services on a fixed-fee basis, Artiva and/or an independent accounting firm appointed by Artiva, at Artiva’s sole expense, shall have the right to audit GCLC’s financial records relating exclusively to expenses incurred
by GCLC for a Project during the time such Project is ongoing under this Agreement and for [***] ([***]) years thereafter; provided, that any such audit(s) shall be conducted upon reasonable advance notice to GCLC and during GCLC’s
normal business hours. 
  

	5.	 REGULATORY. 

5.1 Regulatory Inspections. If any Regulatory Authority conducts, or gives notice to GCLC of its intent to
conduct, an inspection at GCLC’s facilities where any Project or Services are being performed or to take any other regulatory action with respect to any Project or Services, then except to the extent prohibited by law or otherwise
impracticable, GCLC shall use best efforts to notify Artiva in writing prior to complying with such demand or request, and Artiva shall have the right to be present at any such inspections and shall have the opportunity to provide, review, and
comment on any responses that may be required. GCLC shall promptly provide Artiva with a copy of the results from any regulatory inspection. Artiva shall bear any costs, fees, penalties and other imposts levied by any Regulatory Authority, if any,
as a result of [***], in each case other than [***]. 

  
 11. 

 5.2 Site Visits and Audits. Artiva or any of its respective
representatives may visit and/or meet with GCLC at reasonable times and with reasonable frequency during normal business hours to observe the progress of the Project and review relevant records. GCLC shall assist Artiva in scheduling such visits.
From time to time as requested by Merck (but not more than once per year except in the case of emergency or for-cause in which case such once per year limit shall not apply), Artiva and Merck shall have
the right to audit GCLC’s facilities located at 107, Ihyeon-ro, 30 beon-gil, Giheung-gu,
Yongin-si, Gyeonggi-do 16924, Republic of Korea. The first audit of the facilities of GCLC will occur within [***] ([***]) months after the Effective Date (or such
longer period of time as agreed to by Artiva, such agreement not to be unreasonably withheld, conditioned, or delayed). Each audit performed by Artiva and/or Merck shall be limited to [***] ([***]) auditors for a maximum of [***] ([***]) days in
duration, and shall be scheduled at least [***] ([***]) weeks in advance. Artiva (including its representatives) shall have the right to be present at such audits. 

5.3 As part of the audit of any facilities of GCLC, the audit may include an audit of GCLC’s supplier qualification
procedures, risk assessments, audit reports or supplier questionnaires and associated corrective actions and Environmental Health and Safety assessments. 

5.4 GCLC shall comply with the applicable terms and conditions of this Section 5.2 and any applicable supply
agreement or quality agreement (including any applicable terms and conditions with respect to audit and inspection rights and compliance, operation and maintenance of the facilities and equipment), and shall make commercially reasonable efforts to
include all such terms and conditions in its agreement with its subcontractors who are manufacturing Merck Products or manufacturing materials used to manufacture Merck Products. In the event that GCLC is unable to include such terms in its
subcontractor agreements, GCLC shall notify Artiva of same and the parties shall discuss and mutually agree upon an appropriate course of action. 

5.5 Artiva shall provide to GCLC an audit report from any audits performed under this Section 5.2 based on
regulations, phase appropriate regulatory guidance documentation and reasonable experience and trends related to such observations. Within [***] ([***]) days after receipt of such audit report from Artiva, GCLC shall deliver to Artiva a corrective
remediation plan addressing any deficiencies observed in the audit. GCLC shall work with Artiva and any permitted subcontractors to conduct the activities set forth in the remediation plan to address and correct the audit observations identified in
good faith. 
 5.6 Record-Keeping. GCLC shall maintain, separated on a Project by Project basis, records of
documents, information, data and materials used or generated in performance of the Services (including, without limitation, Work Product, Arising Intellectual Property, and any related laboratory notebooks, data files and reports) in a professional
manner so as to permit Artiva and Merck to 

  
 12. 

 
review such records pertinent to the Project in accordance with this Section 5.3 without disclosing to Artiva or Merck any third party confidential or proprietary information or other
information of GCLC unrelated to the Project. Artiva shall own all data sets generated by GCLC under this Agreement, which shall be certified by appropriate GCLC personnel that supervised the creation of such data set, and any formal reports shall
require approval by appropriate GCLC and Artiva senior-level personnel. GCLC shall retain the rights to use all data related to GCLC Background IP or Arising GCLC Core IP for purposes other than the research, development, or commercialization of the
Merck Products. The parties shall establish a central repository (e.g., an online data room) for the sharing of such records. Designated representatives of Artiva or Merck shall, upon reasonable notice by Artiva to GCLC, have access to and
shall be permitted to review all such records during the term of this Agreement and during the applicable retention period specified in Section 5.4. Upon Artiva’s reasonable request, GCLC shall provide to Artiva a copy of any or all such
records. 
 5.7 Retention of Records. GCLC shall retain in its possession copies of any and all data, documents
or information related to the performance of this Agreement, in addition to as required for regulatory, legal or insurance purposes. Except as expressly set forth in any Work Order(s), GCLC shall maintain records relating to the Services under any
Work Order until the later of: (i) the [***] ([***]) anniversary of completion of such Services; and (ii) expiration of the minimum retention period required by applicable laws, rules and regulations. 

 

	6.	 OWNERSHIP OF INTELLECTUAL PROPERTY.

 6.1 Rights under Master Agreement. Except as provided in Section 2, each party
understands and agrees that this Agreement does not modify the ownership or rights of GCLC, nor the rights granted to Artiva, with respect to the GCLC Core Technology as established pursuant to the Master Agreement. 

6.2 Ownership of Arising Intellectual Property. 

Inventorship of Arising Intellectual Property will be determined in accordance with principles of U.S. patent law. GCLC shall
own all Arising Intellectual Property invented solely by GCLC employees, and any Arising Intellectual Property invented jointly with employees of Artiva and/or Merck shall be jointly owned between GCLC and Artiva and/or Merck. 

6.3 Patent Prosecution and Enforcement. GCLC shall promptly disclose to Artiva in writing the conception,
creation or discovery of any Arising Intellectual Property to which one or more patent applications may be filed. Artiva may grant to Merck under the Collaboration Agreement any right that Artiva has under the Master Agreement or this Agreement,
including any right to prepare, file, prosecute (including conduct any interferences, reissue proceedings and reexaminations), maintain, enforce, and bring and control any infringement action with respect to any GCLC Core Patents, Joint Patents, or
Patents within the 

  
 13. 

 
Arising Intellectual Property in accordance with the Master Agreement and this Agreement. Filing of patent applications shall indicate GCLC as the owner of the applicable patents, where
appropriate, in accordance with the provision of this Section 6, and Artiva shall promptly disclose to GCLC copies of any and all such patents applications as filed, together with notice of their respective filing dates and serial numbers. 

 

	 	(a)	 Arising GCLC Core IP. Filing, prosecution, and enforcement of patent applications covering Arising GCLC
Core IP shall be governed by Sections 8.2-8.4 of the Master Agreement. Any such patent applications shall not include any reference to or disclosures regarding the Antibody Binders, Collaboration Candidates,
Merck Products, or Arising Merck Product IP. GCLC shall not include any Results in any patent applications within the Arising GCLC Core IP without Artiva’s prior written consent; 

 

	 	(b)	 Arising Merck Product IP. Artiva and/or Merck shall have the right to file, prosecute (including during
administrative proceedings such as interference, derivation, opposition, reexamination, reissue, supplemental examination, Inter Partes Review and Post-Grant Review proceedings), enforce, and defend Arising Merck Product IP, regardless of
ownership or inventorship. GCLC agrees to cooperate fully with Artiva and/or Merck and provide any information and assistance that either may reasonably request for the filing, prosecution and maintenance of the Arising Merck Product IP, including
the execution of any applicable powers of attorney or similar documents. In the event that Artiva and/or Merck is unable to initiate or prosecute an action to enforce or defend Arising Merck Product IP without GCLC, GCLC will join such action
voluntarily and will execute and cause its Affiliates to execute all documents necessary for Artiva and/or Merck to initiate litigation to prosecute and maintain such action. 

 

	7.	 CONFIDENTIALITY. 

7.1 Confidential Information. For purpose of this Agreement, “Confidential
Information” shall mean any and all information disclosed or made available by or on behalf of a party (the “Disclosing Party”) to the other party (the “Receiving Party”), whether in
oral, written, graphic, electronic or other form. However, notwithstanding the foregoing, all Arising GCLC Core IP that is solely owned by GCLC shall be deemed Confidential Information of GCLC, and all Arising GCLC Core IP that is jointly owned
shall be deemed the Confidential Information of both Parties. All Arising Merck Product IP shall be deemed Confidential Information of Artiva, in each case hereunder and under the Master Agreement. 

  
 14. 

 7.2 Exceptions. Confidential Information of a Disclosing Party shall
not include any information that the Receiving Party can demonstrate by competent evidence: (a) is or becomes publicly known other than as a result of any breach of this Agreement by the Receiving Party; (b) is disclosed to the Receiving
Party on a non-confidential basis by a third party who rightfully possesses the information; (c) was known to the Receiving Party prior to its first receipt from the Disclosing Party (provided that the
exception set forth in this clause (c) shall not apply to Results, other Work Product or Arising Intellectual Property); or (d) was independently developed by the Receiving Party outside the scope of this Agreement and without use of or
reference to the Confidential Information of the Disclosing Party. 
 7.3 Confidentiality Obligation. During
the term of this Agreement and thereafter, the Receiving Party shall maintain all Confidential Information of the Disclosing Party as confidential and shall not disclose any such Confidential Information or use any such Confidential Information for
any purpose, except (a) as expressly authorized by this Agreement, (b) as permitted by Section 7.4, or (c) to its employees, agents, consultants, Artiva-approved subcontractors and other representatives who require access to such
information to accomplish the purposes of this Agreement so long as such persons are under obligations regarding the confidentiality of the Confidential Information and the ownership of Work Product and Arising Intellectual Property (including,
without limitation, Arising GCLC Core IP and Arising Merck Product IP) that are consistent with, and no less protective to GCLC than, the terms of this Agreement. The Receiving Party may use the Confidential Information of the Disclosing Party only
to the extent required to accomplish the purposes of this Agreement. The Receiving Party shall use at least the same standard of care as it uses to protect its own confidential information to ensure that its employees, agents, consultants,
sublicensees (including Merck and any of its Affiliates, employees, agents, consultants, sublicensees and subcontractors) GCLC-approved subcontractors and other representatives do not disclose or make any unauthorized use of the Confidential
Information. The Receiving Party shall promptly notify the Disclosing Party upon discovery of any unauthorized use or disclosure of the Confidential Information. 

7.4 Authorized Disclosure. Notwithstanding the provisions of Section 7.3, the Receiving Party may disclose
Confidential Information of the Disclosing Party, without violating its obligations under this Agreement, to the extent the disclosure is required by applicable law or by a valid order of a court or other governmental body having jurisdiction,
provided that the Receiving Party gives reasonable prior written notice to the Disclosing Party of such required disclosure and, at the Disclosing Party’s request and expense, cooperates with the Disclosing Party’s efforts to contest such
requirement, to obtain a protective order requiring that the Confidential Information so disclosed be used only for the purposes for which the order was issued or the law or regulation required, and/or to obtain other confidential treatment of the
Confidential Information so disclosed. 

  
 15. 

 7.5 GCLC Press Release. A public announcement may be made by GCLC on
or following the date hereof substantially in the form attached hereto as Exhibit F. 
 7.6 Third Party
Confidential Information. The Disclosing Party shall not disclose to the Receiving Party any confidential or proprietary information that belongs to any third party. 
  

	8.	 REPRESENTATIONS AND WARRANTIES. 

8.1 Mutual Representations and Warranties. Each party represents and warrants that (a) it has full power and
authority to enter into this Agreement, (b) this Agreement has been duly authorized, (c) this Agreement is binding upon it, (d) the terms of this Agreement are not inconsistent with its other contractual arrangements (including the
Collaboration Agreement, as represented and warranted by Artiva), and (e) it is not constrained by any existing agreement in providing complete disclosures to the other party concerning obligations to be performed under this Agreement. 

8.2 GCLC Representations and Warranties. GCLC represents and warrants that: (a) GCLC will render the Services in
accordance with high professional standards customary to its industry and in compliance with the terms of this Agreement, the terms of the Work Orders, and all applicable laws, rules and regulations; and (b) the personnel assigned to perform
Services rendered under this Agreement shall be qualified and professionally capable of performing the Services. GCLC further represents and warrants that, as of the Effective Date, there are no pending warnings (i.e., warnings to which GCLC
has not responded) issued to GCLC by any Regulatory Authority relating to services it has provided to third parties relating to any clinical trial. 

8.3 Artiva Representations and Warranties. Artiva represents and warrants that: (a) as of the effective
date, except for a Supply Agreement and/or Quality Agreement (to be negotiated), the Collaboration Agreement attached hereto in Exhibit C hereto is the entire agreement between Artiva and Merck with respect to the subject matter hereof, and
there is no separate agreement, consideration or undertaking between Artiva and/or Merck with respect to Merck Products; (b) the Collaboration Agreement as executed will be consistent with the licenses and rights granted to Artiva hereunder;
and (c) Artiva will render its activities under this Agreement, if any, in accordance with high professional standards customary to its industry and in compliance with the terms of this Agreement, the terms of the Work Orders, and all
applicable laws, rules and regulations. 

  
 16. 

 8.4 No Debarment. The mutual covenant in Section 11.3(a) of the
Master Agreement is incorporated by reference herein and deemed to also apply with respect to the performance of the Services by GCLC and the use of the Work Product and Arising Intellectual Property by Artiva, in each case with respect to the Merck
Products. 
 8.5 Anti-Bribery. Each party represents, warrants and covenants that it and its officers, employees,
directors, consultants, contracts and agents, in connection with the performance of its respective obligations under this Agreement, shall not cause the other party to be in violation of any applicable anti-bribery legislations anywhere in the
world. 
 8.6 Disclaimer of Warranties. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES
ANY REPRESENTATION OR WARRANTY TO THE OTHER PARTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF TITLE, NON-INFRINGEMENT, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE.

 8.7 Limitation of Liability. EXCEPT FOR BREACH OF ARTICLE 7, IN NO EVENT SHALL EITHER PARTY BE LIABLE
TO THE OTHER FOR ANY LOST PROFITS, LOST SAVINGS, OR ANY OTHER INCIDENTAL, SPECIAL, EXEMPLARY, OR CONSEQUENTIAL DAMAGES, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT;
provided, however, that this Section 8.7 shall not be construed to limit either party’s indemnification obligations under Article 10. 
  

	9.	 TERM AND TERMINATION. 

9.1 Term. The term of this Agreement shall commence on the Effective Date and, unless earlier terminated in
accordance with this Article 9, shall expire upon the termination of the Collaboration Agreement. 
 9.2
Termination for Material Breach. Each party shall have the right to terminate this Agreement in its entirety or any Work Order immediately upon written notice to the other party if the other party materially breaches its obligations under
this Agreement or any Work Order and, after receiving written notice identifying such material breach in reasonable detail, fails to cure such material breach within 60 days from the date of such notice (or within 30 days from the date of such
notice in the event such material breach is solely based on the breaching party’s failure to pay any amounts due hereunder); provided, however, in the case of a breach or violation that cannot be cured within such 60 day period, the non-breaching party may terminate this Agreement or the applicable Work Order following such 60 day period only if the breaching party shall have failed to commence substantial remedial actions within such 60 day
period and to use reasonable efforts to pursue the same. Any right to terminate under this Section 9.2 shall be stayed and the cure period tolled in the event that, during any cure period, the breaching party shall have initiated dispute
resolution 

  
 17. 

 
in accordance with Section 11.5 with respect to the alleged breach, which stay and tolling shall last so long as the breaching party diligently and in good faith cooperates in the prompt
resolution of such dispute resolution proceedings. Either party may terminate any Work Order immediately upon written notice to the other party if the other party is in breach of Section 8.4. Each party shall be entitled to offset, against
amounts payable to the other party under this Agreement, any amounts of damages determined, in a final decision by the applicable court action or other legal proceeding, to be owed to such party by the other party based on the other party’s
material breach of this Agreement. If such notice of breach is for breach of a Work Order, such notice shall note the specific Work Order under which such breach is claimed. 

9.3 Termination at Will. Artiva may terminate any Work Order without cause upon 90 days’ prior written
notice to GCLC. 
 9.4 Consequences of Termination. In the event of early termination of any individual Work
Order for a Project, or in the event of termination of all Work Orders for all Projects by Artiva for reasons stated above, Artiva shall pay to GCLC all sums owing to GCLC for Services completed up to the effective termination date of such Work
Order(s) and all non-cancelable obligations reasonably incurred before the effective date of termination pursuant to such Work Order(s) within 30 days after the effective date of termination. Subject to
the preceding sentence, GCLC shall refund to Artiva any prepaid amounts not earned by GCLC prior to the date of such termination, in which event, the parties shall mutually discuss in good faith any compensation and costs payable to GCLC for its
preparatory work to conduct any Work Order, including non-cancelable costs and compensations for its subcontractors. In the event that this Agreement is terminated under Section 9.2 due to Artiva’s
material breach of this Agreement (other than a material breach by Artiva arising due to Merck’s material breach of its obligations under the Collaboration Agreement), GCLC agrees to allow Merck to step in and cure the breach (to the extent the
breach is curable) and assume Artiva’s rights and obligations under this Agreement within a reasonable period to be agreed upon between GCLC and Merck. In this case, the licenses and exclusivity provided for in Sections 2.2 and 2.4 shall
continue through the Merck Product Term subject to Merck’s cure of such material breach (to the extent the breach is curable) and assumption of Artiva’s payment obligations owed to GCLC under this Agreement. In the event that this
Agreement is terminated by Artiva under Section 9.2 due to GCLC’s breach, the licenses and exclusivity provided for in Sections 2.2 and 2.4 shall continue through the Merck Product Term, and with respect to any Merck Product at the time of
termination under Section 9.2, if the criteria have been met under the Collaboration Agreement for Artiva to receive any applicable milestone payments attributable to (i) [***] and (ii) [***], then Artiva shall be obligated to continue to pay
Merck Product Payments to GCLC with respect to such Merck Product during the Merck Product Term. For clarity, in the event of termination, the requirements of Section 10.5(c) in the Master Agreement shall not apply. 

  
 18. 

 9.5 Survival. Expiration or termination of this Agreement
shall not relieve the parties of any obligation accruing prior to such expiration or termination. Sections 2.1 (last sentence only), 2.2, 2.4, 3.5, 3.6, 4.3, 5.1, 5.3, 5.4, 8.6, 8.7,and 9.4 and 9.5, and Articles 6, 7 and 10 shall survive
expiration or termination of this Agreement. 
  

	10.	 INDEMNIFICATION. 

10.1 Artiva Indemnification. Artiva hereby agrees to save, defend, indemnify and hold harmless GCLC and its
officers, directors, employees, consultants and agents (“GCLC Indemnitees”) from and against any and all losses, damages, liabilities, expenses and costs, including reasonable legal expense and
attorneys’ fees (“Losses”), to which any such GCLC Indemnitee may become subject as a result of any suit, claim, demand, action or other proceeding by any third party (in each case, a
“Third Party Claim”), to the extent such Losses arise out of: (a) the material breach by Artiva of any representation, warranty, covenant or agreement made by it under this Agreement;
(b) the gross negligence or willful misconduct of any Artiva Indemnitee (as defined below); (c) the development, manufacture, use, handling, storage, sale or other disposition of any Merck Product or the exploitation of Work Product by or
on behalf of Artiva or (d) the use of Materials by GCLC in connection with the Services in accordance with the Protocol and Artiva’s instructions, or with respect to any deficiency or defect in Materials; except, in each case, to the
extent such Losses result from the material breach by GCLC of any representation, warranty, covenant or agreement made by it under this Agreement or the negligence or willful misconduct of any GCLC Indemnitee. 

10.2 GCLC Indemnification. GCLC hereby agrees to save, defend, indemnify and hold harmless Artiva and its
officers, directors, employees, consultants, contractors and agents (“Artiva Indemnitees”) from and against any and all Losses to which any such Artiva Indemnitee may become subject as a result of
any Third Party Claim to the extent such Losses arise out of the material breach by GCLC of any representation, warranty, covenant or agreement made by it under this Agreement or the gross negligence or willful misconduct of any GCLC Indemnitee;
except, in each case, to the extent such Losses result from the material breach by Artiva of any representation, warranty, covenant or agreement made by it under this Agreement or the gross negligence or willful misconduct of any Artiva Indemnitee.

 10.3 Indemnification Procedures. A party claiming indemnification under this Article 10 (the
“Indemnitee”) shall promptly notify the other party (the “Indemnitor”) in writing of any action, claim or other matter in respect of which the
Indemnitee or any of its directors, officers, employees and agents intend to claim such indemnification; provided, however, the failure to provide such notice within a reasonable period of time shall not relieve the Indemnitor of any
of its obligations hereunder except to the extent the Indemnitor is materially prejudiced by such failure. The Indemnitor shall not enter into any settlement that would 

  
 19. 

 
adversely affect the Indemnitee’s rights hereunder or impose any obligations on the Indemnitee in addition to those set forth herein without the Indemnitee’s prior written consent. The
Indemnitee may not settle any Third Party Claim without the prior written consent of the Indemnitor, which shall not be unreasonably withheld, conditioned, or delayed. The Indemnitee and its directors, officers, employees and agents shall cooperate
fully with the Indemnitor and its legal representatives in the investigation and defense of any action, claim or other matter covered by the indemnification obligations of this Section 10.3. The Indemnitee may participate in such defense by
counsel of its own selection and at its own expense. 
 10.4 Conflict of Interest. Notwithstanding anything to
the contrary contained in this Agreement, if a conflict of interest exists between the parties with respect to a Third Party Claim for which indemnification is sought by one or both parties, or if the assumption and conduct of the defense by the
Indemnitor would adversely affect the Indemnitee in any manner or prejudice its ability to conduct a successful defense, then the Indemnitee may be separately represented with respect to such Third Party Claim by legal counsel reasonably acceptable
to the Indemnitor and at the Indemnitor’s expense. 
 10.5 Insurance. GCLC, at its own expense, shall
secure and maintain in full force and effect throughout the term of this Agreement insurance coverage for general, professional and contractual liability (including errors and omissions coverage) in commercially reasonable amounts in light of
GCLC’s obligations hereunder with a reputable A-rated insurance company. In addition, GCLC shall secure and maintain in full force and effect throughout the term of this Agreement workers’
compensation insurance in the amount required by the laws of any country in which any of GCLC’s employees performing Services hereunder are located. GCLC shall provide a certificate of insurance evidencing the required coverage under this
Section 10.5 to Artiva upon request. Notwithstanding, it is understood that such insurance shall not be construed to create a limit of Artiva’s liability with respect to its indemnification obligation under this Article 10 or any other
liability to compensate GCLC under this Agreement. 
  

	11.	 GENERAL PROVISIONS. 

11.1 No Implied Licenses. No right or license is granted under this Agreement by either party to the other, either
expressly or by implication, except those specifically set forth herein. 
 11.2 Independent Contractor Relationship.
GCLC’s relationship with Artiva is that of an independent contractor, and nothing in this Agreement should be construed to create a partnership, joint venture, or employer-employee relationship. Each party is not an agent of the other party and
is not authorized to make any representation, contract, or commitment on behalf of such other party. Each party shall be responsible for all of its tax returns and payments required to be filed with or made to any national, state or local tax
authority with respect to transaction contemplated under this Agreement. 

  
 20. 

 11.3 Use of Names. Neither party shall use the other
party’s name or the names of the other party’s employees in any advertising or sales promotional material or in any publication without prior written permission of the other party, except in the case of required regulatory submissions
(with prior written notice to the other party),    However, in its use of the Arising GCLC Core IP with or towards any third party, Artiva shall clearly indicate that the ownership of any and all intellectual property rights
thereof belongs to GCLC if and as required by the Master Agreement. 
 11.4 Successors and Assigns. Neither
party may assign this Agreement without the prior written consent of the other party; provided, however, that Artiva may assign this Agreement without GCLC’s consent in connection with the transfer or sale of all or substantially all of
the business of Artiva to which this Agreement relates, whether by merger, sale of stock, sale of assets or otherwise. Any attempted assignment of this Agreement not in compliance with this Section 11.4 shall be null and void. No assignment
shall relieve either party of the performance of any accrued obligation that such party may then have under this Agreement. This Agreement shall inure to the benefit of and be binding upon each party signatory hereto, its successors and permitted
assigns. 
 11.5 Dispute Resolution. The parties agree that any controversy or claim arising out of, relating
to or in connection with any provision of this Agreement, if and when a dispute arises under this Agreement, that is not resolved by mutual written agreement of the parties (a “Claim”), shall, upon the written request of
either party to the other party, be resolved by final and binding arbitration administered by the International Centre for Dispute Resolution (“ICDR”) in accordance with the then-effective provisions of its International
Arbitration Rules (the “Rules”), except to the extent any such Rule conflicts with the express provisions of this Section 11.5. Capitalized terms used but not otherwise defined in this Section 11.5 shall have the
meanings provided in the Rules. The parties agree that: 
 (a) The arbitration shall be conducted by three (3) arbitrators (the
“Arbitrators”), none of whom shall be a current or former employee or director, or a current stockholder, of either party or any of their respective Affiliates. Each party shall appoint one Arbitrator within [***] ([***])
days after submission of the Answer to the Notice of Arbitration, and the two-party appointed shall appoint a third Arbitrator, who shall serve as chair of the tribunal, within [***] ([***]) days after the
appointment of the later-appointed Arbitrator. If any of the Arbitrators are not appointed within the time prescribed above, then the ICDR shall appoint the Arbitrator(s) in accordance with its International Arbitration Rules. 

(b) The arbitration and all associated discovery proceedings and communications shall be conducted in English. The seat of the
arbitration shall be Singapore. The Award rendered by the Arbitrators shall be final, binding and non appealable, and judgment may be entered upon it in any court of competent jurisdiction. The Arbitrators shall have no authority to award punitive
or any other type of damages not measured by a party’s compensatory damage. The Arbitrators will, in rendering their decision, apply the substantive law of the laws of the State of New York, U.S., excluding its conflicts of laws principles.
Each party shall bear its own attorney’s fees, costs, and disbursements arising out of the arbitration, and shall pay an equal share of the fees and costs of the Arbitrators. 

  
 21. 

 (c) Notwithstanding the foregoing, nothing contained in this Agreement shall deny
either party the right to seek injunctive or other equitable relief from a court of competent jurisdiction in the context of a bona fide emergency or prospective irreparable harm, and such an action may be filed and maintained notwithstanding any
ongoing discussions between the parties or any ongoing arbitration proceeding. In addition, either party may apply to the Arbitrators for interim injunctive relief until the arbitration award is rendered or the controversy is otherwise resolved.
Except to the extent necessary to confirm an award or as may be required by applicable laws, neither party nor any Arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of both parties. In no
event shall an arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute, controversy or claim would be barred by the applicable statute of limitations. 

11.6 Governing Law. Resolution of all disputes, controversies or claims arising out of, relating to or in connection
with this Agreement or the performance, enforcement, breach or termination of this Agreement and any remedies relating thereto, shall be governed by and construed under the substantive laws of the State of New York, U.S., without regard to conflicts
of law rules. 
 11.7 Entire Agreement; Amendment. This Agreement, including its Exhibits (if any) and Work Orders,
constitutes the final, complete and exclusive agreement of the parties with respect to the subject matter hereof and supersedes all prior understandings and agreements relating to its subject matter, except, for the avoidance of doubt, the Master
Agreement. This Agreement may not be changed, modified, amended or supplemented except by a written instrument signed by both parties. 

11.8 Non-Waiver. No failure or delay of one of the parties to insist upon
strict performance of any of its rights or powers under this Agreement shall operate as a waiver thereof, nor shall any other single or partial exercise of such right or power preclude any other further exercise of any rights or remedies provided by
law. Any waiver by a party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be executed by an authorized officer of the waiving party. 

11.9 Severability. If any provision of this Agreement is found by a court of competent jurisdiction to be unenforceable,
then such provision shall be construed, to the extent feasible, so as to render the provision enforceable, and if no feasible interpretation would save such provision, it shall be severed from the remainder of this Agreement. The remainder of this
Agreement shall remain in full force and effect, unless the severed provision is essential and material to the rights or benefits received by either party. In such event, the parties shall negotiate, in good faith, and substitute a valid and
enforceable provision or agreement that most nearly implements the parties’ intent in entering into this Agreement. 

  
 22. 

 11.10 Notices. Any notice required or permitted to be given under
this Agreement must be in writing and delivered either in person, by any method of mail (postage prepaid) requiring return receipt, by overnight courier or by electronic mail, to the party to be notified at its address given below, or at any address
such party has previously designated by prior written notice to the other. Notice shall be deemed sufficiently given for all purposes upon the earliest of: (a) the date of actual receipt; (b) if mailed by international courier, seven
(7) days after the date of postmark; (c) if delivered by international express courier, three (3) days after the date of pick up; or (d) if delivered by electronic mail, upon confirmation of transmission. 

 

			
	If to Artiva:	 	Artiva Biotherapeutics, Inc.
		 	4747 Executive Drive, Suite 1150
		 	San Diego, CA 92121
		 	USA
		 	Attention: Chief Executive Officer
		 	Email: [***]
		
	If to GCLC:	 	Green Cross LabCell Corporation
		 	107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si,
		 	Gyeonggi-do, 446-850, 16924, Republic of South Korea.
		 	Attention: Chief Executive Officer
		 	Email: [***]

 11.11 Force Majeure. In the event of a delay caused by inclement weather, fire, flood,
epidemic, quarantine, strike or other labor dispute, act of God, act of governmental officials or agencies, or any other cause beyond the control of the parties, the party or parties so affected shall be excused from performance hereunder for the
period of time attributable to such delay, which may extend beyond the time lost due to one or more of the causes mentioned above. In the event of any such delay, the parties may, in their sole discretion, amend this Agreement or any Work Order, as
appropriate, by mutual written agreement. 
 11.12 Interpretation. The headings of clauses contained in this Agreement
preceding the text of the sections, subsections and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its interpretation or construction. All
references in this Agreement to the singular shall include the plural where applicable. Unless otherwise specified, references in this Agreement to any section shall include all subsections and paragraphs in such Section and references in this
Agreement to any subsection shall include all paragraphs in such subsection. All references to days in this Agreement shall mean calendar days, unless otherwise specified. Ambiguities and uncertainties in this Agreement, if any, shall not be
interpreted against either party, irrespective of which party may 

  
 23. 

 
be deemed to have caused the ambiguity or uncertainty to exist. This Agreement has been prepared in the English language, and the English language shall control its interpretation. In addition,
all notices required or permitted to be given hereunder, and all written, electronic, oral or other communications between the parties regarding this Agreement, shall be in the English language. 

11.13 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original and all of
which together shall constitute one and the same instrument. This Agreement may be executed via electronic signature or via the exchange of signed portable document format (“PDF”) versions of this Agreement. Such electronic
signatures, and signatures on PDF versions of this Agreement, will be considered the legally binding equivalent of wet-ink, original, hand-written signatures. 

[Signature Page Follows] 

  
 24. 

 IN WITNESS WHEREOF,
the parties have by duly authorized persons executed this Agreement as of the Effective Date. 
  

									
	ARTIVA BIOTHERAPEUTICS, INC.	 		 	GREEN CROSS LABCELL CORPORATION
					
	 By:
  

Name:
  

Title:
  

Date:
	 	 /s/ Fred Aslan, MD
  

Fred Aslan, MD
  

Chief Executive Officer
  

January 28, 2021
	 	             

 
 
  

  

	 	 By:
  

Name:
  

Title:
  

Date:
	 	 /s/ Dae-Woo Park

 
 Dae-Woo Park

 
 Chief Executive Officer

 
 January 27, 2021

  

  
 25. 

 Exhibit A 

[***] 

 Exhibit B 

[***] 

  
 27. 

 Exhibit C 

[***] 

  
 28. 

 Exhibit D 

[***] 

  
 29. 

 Exhibit E 

[***] 

  
 30. 

 Exhibit F 

Press Release 
  
 

 
  
 

 

  
 31. 

 

 

  
 32.EX-10.24

 Exhibit 10.24 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE
TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
 Dated November 5, 2020 

Affimed GmbH 
 and 

Artiva Biotherapeutics, Inc. 
  

 
  

Strategic Collaboration Agreement 
  

 
  

 Table of Contents 

 

							
	 1.
	 	 Definitions
	  	 	3	
			
	 2.
	 	 Preclinical Assessment
	  	 	8	
			
	 3.
	 	 Supply of Proprietary Compounds for Preclinical Assessment.
	  	 	11	
			
	 4.    
	 	 Financial Provisions
	  	 	11	
			
	 5.
	 	 Intellectual Property
	  	 	12	
			
	 6.
	 	 Confidentiality
	  	 	16	
			
	 7.
	 	 Governance
	  	 	18	
			
	 8.
	 	 Representations and Warranties
	  	 	20	
			
	 9.
	 	 Indemnification / Limitation of Liability.
	  	 	21	
			
	 10.
	 	 Term and Termination
	  	 	23	
			
	 11.
	 	 General Provisions
	  	 	26	
		
	 Annex 1 Preclinical Assessment Plan – Template
	  			

  
 2|30 

 STRATEGIC COLLABORATION AGREEMENT 

This Strategic Collaboration Agreement (Agreement) is made and entered into as of November 5, 2020 (the Effective Date) by
and between Affimed GmbH, a German corporation having its principal office at Im Neuenheimer Feld 582, 69120 Heidelberg, Germany (Affimed) and Artiva Biotherapeutics, Inc. (Artiva), a US corporation having its principal
office at, 4747 Executive Drive #1150, San Diego, CA 92121, USA (Artiva), (Affimed and Artiva each a Party and together the Parties). 

PREAMBLE 
 WHEREAS, Affimed
owns or controls certain rights in relation to its proprietary Innate Cell Engagers, including [***] (the Affimed Compound(s)) and Artiva owns or controls certain rights in relation to its proprietary allogeneic natural killer cell
products, including AB-101 (the Artiva Cell Product(s)); 
 WHEREAS, the Parties wish to
establish an exclusive relationship to evaluate the therapeutic potential of combining their platform technologies with the goal of identifying one or more co-vialed Combination Products (as defined below)
combining an Affimed Compound with an Artiva Cell Product, including preclinical assessments of such potential Combination Products; and 
 WHEREAS,
the joint preclinical assessment activities of such Combination Products shall be based on a [***] sharing of costs, unless otherwise specified in this Agreement. 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties, intending to be legally bound, hereby
agree as follows: 
  

	1.	 Definitions 

Capitalized terms used in this Agreement shall have the meanings as defined herein: 

Affiliate shall mean, with respect to any person or entity, any other person or entity which directly or indirectly controls, is
controlled by, or is under common control with such person or entity. A person or entity shall be regarded as in control of another person or entity if it owns, or directly or indirectly controls, more than fifty percent (50%) of the voting stock or
other ownership interest of the other person or entity, or if it directly or indirectly possesses the power to direct or cause the direction of the management and policies of the other person or entity by any means whatsoever. 

Affimed Compounds has the meaning set forth in the Preamble. 

Affimed Improvement means any Foreground IP which (i) constitutes an improvement or enhancement to, or relates specifically
to, Affimed’s Background IP, including the Affimed Compound(s) and its manufacture or use, and (ii) does not constitute an improvement to, nor relates specifically to, any Artiva Background IP. 

Alliance Manager has the meaning set forth in Section 7.1. 

  
 3|30 

 Applicable Law means any law or statute, any rule or regulation issued by a
government authority (including courts and Regulatory Authorities), any GxP regulations or guidelines, applicable guidelines of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (“ICH”,
in particular ICH Topic E8 (General Considerations for Clinical Trials)) as well as and any judicial, governmental, or administrative order, judgment, decree or ruling, in each case as applicable to the subject matter and the parties at issue. 

Assessment Period means a [***] following the completion of all activities contemplated by a Preclinical Assessment Plan. 

Artiva Cell Products has the meaning set forth in the Preamble. 

Artiva Improvement means any Foreground IP which (i) constitutes an improvement or enhancement to, or relates specifically
to, Artiva’s Background IP, including the Artiva Cell Product and its manufacture or use, and (ii) does not constitute an improvement to, nor relates specifically to, any Affimed Background IP. 

Background IP means any IP or Know-how owned or Controlled by a Party which has been
developed, conceived, first reduced to practice or rightfully acquired by a Party prior to the Effective Date hereof, or during the Term (but outside of the Parties’ collaboration hereunder). 

Budget shall mean the budget attached to each Preclinical Assessment Plan. 

[***] 
 Change
of Control means, with respect to a Party to which this Agreement relates, (a) a merger, reorganization, consolidation or other transaction involving such Party and any entity that is not an Affiliate of such Party as of the Effective
Date, which results in the voting securities of such Party outstanding immediately prior thereto ceasing to represent at least fifty percent (50%) of the combined voting power of the surviving entity immediately after such merger, reorganization,
consolidation or other transaction, or (b) any entity that is not an Affiliate of such Party as of the Effective Date becoming the beneficial owner of fifty percent (50%) or more of the combined voting power of the outstanding securities of
such Party, or (c) any entity that is not an Affiliate of such Party as of the Effective Date acquiring the power (whether through ownership interest, contractual right, or otherwise, including the result of any government action) to direct or
cause the direction of the management and policies of such Party. 
 Combination Product means a pharmaceutical product created
pursuant to a Preclinical Assessment Plan that combines an Affimed Compound and the Artiva Cell Product in one co-vialed, co-manufactured, or co-cryopreserved therapy. 
 Collaboration Targets means EGFR[***] 

Confidential Information means all nonpublic information, data, documents, including
Know-how and the subject-matter of any unpublished Invention, or any material, whether in written, oral, graphical, machine-readable or other form, whether or not marked as confidential, that is disclosed or
made available under this Agreement or the 

  
 4|30 

 Prior Confidentiality Agreement by the Disclosing Party to the Receiving Party. Subject to
statutory disclosure requirements, the existence and contents of this Agreement shall constitute Confidential Information of either Party. The Affimed Improvements shall constitute Confidential Information of Affimed, and the Artiva Improvements
shall constitute Confidential Information of Artiva. Joint IP that constitute Confidential Information shall constitute Confidential Information of both Parties and each Party shall have the right to use and disclose such Confidential Information
consistent with Article 6. 
 Control means, with respect to any information, Know-how
or Intellectual Property Right, possession by a Party of the ability to grant the right (whether by ownership, license or otherwise) to access or use, or to grant a license or a sublicense to, or to use such information, Know-how or Intellectual Property Right to the other Party as provided for herein without violating the terms of any agreement or other arrangement with any Third Party. 

Development Candidate means a potential product candidate that combines an Affimed Compound and an Artiva Cell Product in one co-vialed or co-manufactured therapy, and which targets one Collaboration Target. 

Costs means the actual costs and expenses incurred by a Party for any Preclinical Assessment, including, as applicable: 

[***] All Costs will be budgeted and reported in USD. If actual costs and expenses incurred by a Party are in a different currency, the
currency conversion will be calculated using the monthly average exchange rate of the month in which the costs or expenses were incurred, as published in the Wall Street Journal. 

Disclosing Party has the meaning set forth in Section 6.1. 

Effective Date is defined in the introductory paragraph to this Agreement. 

EGFR means epidermal growth factor receptor. 

  
 5|30 

 EMA means the European Medicines Agency, and any successor agency thereto.

 FDA means the U.S. Food and Drug Administration, or any successor agency thereto. 

Foreground IP means any IP or Know-how which is developed, conceived, first reduced to
practice or rightfully acquired during the Term by a Party or its Affiliates alone, or by the Parties jointly, in each case as a result of the activities under this Agreement. 

FTE means a full-time employee of a Party working over the course of a twelve (12) month period, or several employees of a
Party collectively working the equivalent of such full-time employee. FTEs shall be calculated based on the time an employee of the Parties spends working on a billable effort as recorded by such Parties’ project time reporting system. 

FTE Rate means the mutual annual rate per FTE of either Party as set forth in the Preclinical Assessment Plans. 

Good Clinical Practice or GCP shall mean any and all laws, rules, regulations, guidelines and generally accepted
standards and requirements regarding the ethical conduct of clinical trials promulgated or endorsed by a Regulatory Authority of competent jurisdiction, including the relevant regulations set forth in U.S. Code of Federal Regulations (CFR) Title 21,
ICH GCP Guidelines E6(R2), current step 5 version, dated 14 June 2017, as amended from time to time, national legislation implementing European Community Directive 2001/20/EC of 4 April 2001 on the approximation of the laws, regulations
and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use, European Community Directive 2005/28/EC of 8 April 2005 laying
down principles and detailed guidelines for good clinical practice as regards to investigational medicinal products for human use and European Community Regulation 2014/536/EU dated 14 April 2014, as amended from time to time. 

Good Laboratory Practice or GLP shall mean any and all laws, rules, regulations, guidelines and generally accepted
standards and requirements regarding quality control for laboratories to ensure the consistency and reliability of results promulgated or endorsed by a Regulatory Authority of competent jurisdiction, including the relevant regulations set forth in
CFR Title 21, national legislation implementing European Community Directive 2004/9/EC of 11 February 2004 on the inspection and verification of good laboratory practice (GLP) as amended and European Community Directive 2004/10/EC of
11 February 2004 on the harmonization of laws, regulations and administrative provisions relating to the application of the principles of good laboratory practice and the verification of their applications for tests on chemical substances as
amended, OECD Series on Principles of Good Laboratory Practice and Compliance Monitoring. 
 Good Manufacturing Practice or
GMP shall mean any and all laws, rules, regulations, guidelines and generally accepted standards and requirements regarding the quality control and manufacturing of pharmaceutical products promulgated or endorsed by a Regulatory
Authority of competent jurisdiction, including the relevant regulations set 

  
 6|30 

 
forth in CFR Title 21, ICH GMP Guidelines Q7, current step 5 version, dated 10 November 2000, as amended from time to time, national legislation implementing European Community Directive
91/356/EEC of 13 June 1991 laying down the principles and guidelines of good manufacturing practice for medicinal products for human use as amended by European Community Directives 2003/94/EC, the Rules Governing Medicinal Products in the
European Community, Volume 4, including annexes. 
 GxP means GCP, GLP or GMP or any combination thereof, as applicable. 

IND means an Investigational New Drug application filed with the FDA, a Clinical Trial Application filed with the EMA or any
equivalent in any country where a regulatory filing is required or obtained for commencement of human clinical trials of a pharmaceutical product. 

Infringement Proceeding has the meaning set forth in Section 5.7.4. 

Innate Cell Engager means an engineered protein with a non-natural immunoglobulin (e.g.
IgA, D, E, G or M) structure designed to engage with a target on the surface of an immune effector cell (e.g. NK cell or macrophage) and a specific target on a tumor cell. 

Intellectual Property Rights or IP means, with respect to any technology, all existing and future intellectual
property rights (but excluding any Know-How) relating to such technology, including all Patent Rights as well as legally protected trade secrets, copyrights and other intellectual property rights of any kind.

 Joint IP has the meaning set forth in Section 5.2. 

Joint Patent Rights has the meaning set forth in Section 5.5. 

Know-How means any data, results, information,
know-how, trade secrets, techniques, methods, processes, protocols, inventions, modifications, designs or materials of any type or kind, patentable or otherwise, but excluding any of the foregoing to the
extent claimed by any issued Patent Right. 
 Lead IP Party has the meaning set forth in Section 5.5. 

Losses has the meaning set forth in Section 9.2.1. 

Negotiation Period means a [***] following the Option Period. 

Option Period means a [***] following the Assessment Period. 

Patent Right means (a) all patent applications filed or having legal force in any country or jurisdiction, including all
provisional patent applications; (b) all patents that have issued or in the future will be issued from such applications, including method, process, utility, model and design patents and certificates of invention; and (c) all divisionals,
continuations, continuations in part, supplement protection certificates, reissues, re-examinations, renewals, extensions or additions to any such patent application and patents. 

  
 7|30 

 Preclinical Assessment means any and all research, development, and
manufacturing activities undertaken by or on behalf of either Party with respect to a Development Candidate pursuant to a Preclinical Assessment Plan. These activities may include studies to compare the activity of individual and combined product
candidates using in vitro and in vivo assays; studies to identify methods of most effectively generating Combination Products from the Development Candidates; and other activities to be set forth in the Preclinical Assessment Plan for
each Development Candidate in order for the Parties to jointly determine whether to proceed with further Development of one or more of the Development Candidates. The allocation of responsibility for any Preclinical Assessment activities and costs
to either Party shall be set forth in the applicable Preclinical Assessment Plans. 
 Preclinical Assessment Plan means a
written research plan agreed between the Parties which describes and allocates responsibilities for the Preclinical Assessment work to be performed by each Party in relation to a Development Candidate, as well as the Budgets, costs, timelines,
allocation of FTEs and other relevant items agreed between the Parties. A template Preclinical Assessment Plan is attached hereto as Annex 1. 

Prior Confidentiality Agreement means the Mutual Confidentiality Agreement by and between the Parties, dated [***]. 

Proprietary Compound means any Affimed Compound and/or any Artiva Cell Product, as applicable. For clarity, the term Proprietary
Compound does not include any Combination Product or Development Candidate. 
 Receiving Party has the meaning set forth in
Section 6.1. 
 Regulatory Authority means any federal, national, multinational, state, county, city, provincial, or local
regulatory agency, department, bureau or other governmental entity with authority over the marketing, commercialization, manufacture or sale of a pharmaceutical product in a country or jurisdiction, including the FDA in the United States and the EMA
in the EU. 
 Steering Committee has the meaning set forth in Section 7.2. 

Subcontractor(s) has the meaning set forth in Section 11.5. 

Term shall have the meaning set forth in Section 10.1. 

Third Party means any person or entity other than the Parties and their Affiliates. 

 

	2.	 Preclinical Assessment 

 

	 	2.1	 Preclinical Assessment. Subject to the terms and conditions of this Agreement, the Parties shall conduct
Preclinical Assessments of one or more Development Candidates as set forth in a Preclinical Assessment Plan for each Development Candidate. 

  

	 	2.2	 Preclinical Assessment Plans. The details of the Preclinical Assessment activities for each Development
Candidate and the allocation of the costs and 

  
 8|30 

	 	
responsibility for any Preclinical Assessment activity to either Party shall be set forth in each Preclinical Assessment Plan. Within [***] following the Effective Date, the Parties shall, via
the Steering Committee, prepare and agree on the Preclinical Assessment Plans with respect to [***]. The Parties may agree to develop a Preclinical Assessment Plan for a third Development Candidate (involving a suitable Affimed Compound nominated by
Affimed and agreed to by the Steering Committee), within [***] after the Effective Date. Additional Preclinical Assessments may be added during the Term of this Agreement upon the recommendation of the Steering Committee and through a written
amendment to this Agreement. The Steering Committee shall regularly review the Preclinical Assessment Plans in order to amend or update the Preclinical Assessment Plans as necessary. Furthermore, each Party may recommend changes to the Preclinical
Assessment Plans at any time; provided, however, that such changes shall be effective only upon approval by the Steering Committee (as documented in written minutes of the Steering Committee), and upon notice to each Party’s respective Alliance
Manager and Legal Department. Each Party shall use commercially reasonable efforts to conduct its respective obligations set forth in the Preclinical Assessment Plans. Each Party shall perform, and shall ensure that its applicable Affiliates and
Third Party contractors perform, its obligations under the Preclinical Assessment Plans in accordance with high scientific and professional standards, and in compliance with all material respects within the requirements of Applicable Laws, including
GxP. Prior to the expiration of the [***] 

  

	 	2.3	 Results and Reporting. Each Party shall keep the other Party fully informed as to its progress, results
(including the development of any technology or inventions), status and plans in connection with its activities under each Preclinical Assessment Plan. Such information shall be given by periodic, informal oral reports among the representatives of
the Parties as well as formal reports to the Steering Committee in intervals and a format to be agreed by the Steering Committee. 

  

	 	2.4	 Maintenance of Records. Each Party shall maintain records of the activities conducted by or on behalf of
such Party under the Preclinical Assessment Plan, in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes, which shall reflect the work done and the results achieved in the performance of the Preclinical
Assessment Plan in a reasonable level of detail customary for companies engaged in biopharmaceutical research. Upon request, each Party shall make such records available to the other Party. 

 

	 	2.5	 Completion of Preclinical Assessments, Assessment Period, and Option to Pursue Further
Development. Upon completion of the activities set forth in a Preclinical Assessment, the Parties shall use the [***] Assessment Period to discuss and decide in good faith whether additional preclinical assessment activities are required with
respect to a Development Candidate, in which case the Parties shall agree on an amendment to the Preclinical Assessment Plan to add such additional activities, or whether the Preclinical

  
 9|30 

	 	
Assessment Plan activities for that Development Candidate have been completed, in which case the Parties shall work together to draft a report for review by the senior leadership of the Parties,
to be completed within the Assessment Period. Upon the conclusion of the Assessment Period, the Parties [***] to pursue further development of such Development Candidate under a separate agreement to be negotiated in good faith based on the general
commercial terms [***] 

  

	 	2.6	 Materials Transfer. In furtherance of Preclinical Assessment, each Party may provide to the other Party
chemical compounds or biological materials controlled by the supplying Party (collectively, the Materials) for use by the other Party in conducting the Preclinical Assessment for which such other Party is responsible. Except as
otherwise expressly provided under this Agreement, all such Materials delivered to the other Party will remain the sole property of the supplying Party, will be used only in accordance with the Preclinical Assessment and the terms and conditions of
this Agreement, will not be used or delivered to or for the benefit of any Third Party without the prior written consent of the supplying Party, and will be used in compliance with all applicable Laws. The Materials supplied under this Agreement
must be used with prudence and appropriate caution in any experimental work because not all of their characteristics may be known. Except as expressly set forth in this Agreement, THE MATERIALS ARE PROVIDED “AS IS” AND WITHOUT ANY
REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF THE MATERIALS WILL NOT INFRINGE OR VIOLATE ANY PATENT OR
OTHER PROPRIETARY RIGHTS OF ANY THIRD PARTY. 

  

	 	2.7	 Exclusivity. From the Effective Date, and for a period of [***] from [***], neither Party nor its
Affiliates will engage in development and/or commercialization of any co-vialed, co-manufactured or co-cryopreserved combination
product containing [***], except as set forth in this Agreement. [***]. In addition, in the event that the Parties agree upon Preclinical Assessment Plans for additional Development Candidates during the Term, then until the completion of such
Preclinical Assessment Plans and any associated Assessment, Option, or Negotiation Periods, neither Party nor its Affiliates will engage in development and/or commercialization of any co-vialed, co-manufactured or co-cryopreserved combination product 

  
 10|30 

	 	
[***]. For clarity, nothing in this Agreement shall prohibit either Party from developing any monotherapies (including monotherapies based on its Proprietary Compound). [***]. 

 

	3.	 Supply of Proprietary Compounds for Preclinical Assessment. 

 

	 	3.1	 Manufacturing and Supply of Proprietary Compounds. Each Party agrees to manufacture and supply to the
other Party, or procure the manufacturing and supply of, such volumes of its Proprietary Compound reasonably required by the other Party for the Preclinical Assessment Plans. Such supply will be performed [***], unless otherwise agreed by the
Steering Committee. Further details of the supply timing and volumes shall be agreed by the Steering Committee. 

  

	4.	 Financial Provisions 

 

	 	4.1	 Costs. Except as otherwise specified in this Agreement, all Costs incurred by the Parties in the
performance of a Preclinical Assessment Plan shall be shared [***] between the Parties. 

  

	 	4.2	 Control of Costs. The Parties shall only be entitled to incur Costs which are either (i) set forth
in the applicable Preclinical Assessment Plan or (ii) have been agreed and approved in advance by the Steering Committee. The Steering Committee shall review, on at least a quarterly basis, the actual Costs against the Budget agreed under the
Preclinical Assessment Plan. If either Party reasonably considers that it is likely to exceed the Budget of any Costs set forth in the applicable Preclinical Assessment Plan or approved by the Steering Committee, it shall promptly notify the
Steering Committee thereof and shall provide such Steering Committee with details of the additional Costs that it expects to incur and the reason for such increase. The Steering Committee shall then review the information submitted and may, if
appropriate, amend the affected Preclinical Assessment Plan to permit such overrun or to reduce such activities such that no overrun is expected. If the Steering Committee does not approve the additional Costs, the requesting Party shall have the
right to incur such costs on its own behalf (so that the relevant costs items will not form part of the shared Costs mechanism agreed hereunder). However, if the Budget overrun is due to a delay or an advance in timing as to the planned activities,
which activities are in accordance with the relevant Preclinical Assessment Plan, [***] 

  

	 	4.3	 Reporting and Reconciliation of Costs. Within [***] after the end of every calendar quarter, each Party
shall deliver to the Steering Committee a written report showing in reasonable detail the Costs that it has incurred during 

  
 11|30 

	 	
such calendar quarter. Such report shall be in such form as the Steering Committee may reasonably agree from time to time. Within [***] of the receipt of both Parties’ Costs reports, the
Steering Committee (or the Party appointed by the Steering Committee) shall provide to each Party one consolidated financial report for the Costs in accordance with U.S. GAAP and Applicable Law. The Steering Committee shall review such reports and
shall determine any reconciliation amount due by one Party to the other for such calendar quarter to reflect the [***]. [***] 

  

	 	4.4	 Records. Each Party shall maintain records, in sufficient detail, which shall be complete and
accurate and shall fully and properly reflect all Costs incurred by such Party. Upon reasonable request, each Party shall make such records available to the other Party to verify the accuracy of the Costs reported by such Party.

  

	 	4.5	 Value Added Tax. All payments between the Parties under this Agreement are exclusive of any
applicable statutory value added tax or similar tax, if any, which shall be listed separately in the relevant invoice. If any such taxes are payable due to any supplies or services rendered under this Agreement and to the extent such taxes are to be
paid by the Party providing the supply or service to the competent tax authorities, the receiving Party shall pay an amount equal to such taxes to the providing Party upon receipt of a valid invoice allowing for recovery of such taxes.

  

	 	4.6	 Withholding Taxes. If laws, rules or regulations require withholding of income taxes or other taxes
imposed upon payments to be made under this Agreement, the Party owing such payment shall make such withholding payments as required and subtract such withholding payments from the payments to be made hereunder. The Party making such payment shall
promptly deliver to the other Party proof of payment of all such taxes together with copies of all communications from or with such governmental authority with respect thereto, and shall provide such other information and documents as the other
Party may reasonably request in connection such Party’s efforts to claim the tax benefits associated with such payments. The Parties shall use reasonable efforts to minimize any such withholding taxes. 

 

	5.	 Intellectual Property 

 

	 	5.1	 Background IP. Nothing in this Agreement shall affect the ownership of either Party’s Background IP
or imply any license to a Party’s Background IP unless granted expressly. 

  

	 	5.2	 Foreground IP. 

 

	 	5.2.1	 All right, title and interest in all Affimed Improvements shall be owned by Affimed, irrespective of whose
Party’s employees or contractors have made or developed the relevant Affimed Improvement. Artiva hereby 

  
 12|30 

	 	
assigns and transfers to Affimed all of Artiva’ right, title and interest therein and thereto. 

  

	 	5.2.2	 All right, title and interest in all Artiva Improvements shall be owned by Artiva, irrespective of whose
Party’s employees or contractors have made or developed the relevant Artiva Improvement. Affimed hereby assigns and transfers to Artiva all of Affimed’s right, title and interest therein and thereto. 

 

	 	5.2.3	 Except as otherwise provided in Sections 5.2.1 and 5.2.2 above, all rights, title and interest in and to any
Foreground IP generated in the performance of any activities made under the Preclinical Assessment Plan shall be co-owned by Affimed and Artiva in equal shares (Joint IP); provided that the
Parties shall agree to a commercially reasonable royalty or other compensation payable to the other Party for such Joint IP prior to either Party using, exploiting or licensing such Joint IP, in addition to the limitations set forth in
Section 5.1 and Section 5.7 with respect to enforcement of Foreground IP. To the extent any rights in such Joint IP cannot be assigned for co-ownership to the respective other Party under Applicable
Law, the inventing Party shall grant to the other Party a free-of-charge, perpetual, irrevocable, worldwide, royalty-free,
non-exclusive, transferable license, with the right to sublicense through multiple tiers, to practice such non-assignable rights in any manner for any purpose. Each
Party agrees to execute all papers and otherwise agrees to assist the other Party as reasonably required, to perfect in the other Party the rights, title and other interests owned by such Party under this Section and Intellectual Property Rights
relating thereto, as applicable. 

  

	 	5.3	 Licenses. 

  

	 	5.3.1	 License to Artiva. Affimed hereby grants to Artiva a
non-exclusive, worldwide, royalty-free, non-transferable, non-sub-licensable (other than
to Artiva’s Affiliates and Subcontractors) license under its Background IP and any Affimed Improvements during the Term solely to the extent required or useful for Artiva to perform its research obligations under this Agreement.

  

	 	5.3.2	 License to Affimed. Artiva hereby grants to Affimed a
non-exclusive, royalty-free, non-transferable, non-sub-licensable (other than to
Affimed’s Affiliates and Subcontractors) license under its Background IP and any Artiva Improvements during the Term solely to the extent required or useful for Affimed to perform its research obligations in Europe and/or in the United States
under this Agreement. 

  

	 	5.4	 No Further Rights. This Agreement shall not be construed to convey any right or license to either Party
except as specifically stipulated in this Agreement. 

  

	 	5.5	 Prosecution and Maintenance of Patent Rights. 

  
 13|30 

	 	5.5.1	 Affimed shall have the sole right (but not the obligation) to prepare, file, prosecute and defend any Patent
Rights covering its Background IP and/or any Affimed Improvement. 

  

	 	5.5.2	 Artiva shall have the sole right (but not the obligation) to prepare, file, prosecute and defend any Patent
Rights covering its Background IP and/or any Artiva Improvement. 

  

	 	5.5.3	 The Steering Committee shall designate one Party (the Lead IP Party) that is responsible for and
shall control the preparation, filing, prosecution, grant, maintenance and defense of all Patent Rights relating to any Joint IP (Joint Patent Rights) subject to the following requirements: 

 

	 	(i)	 Prior to filing any application for any Joint Patent Right, the Lead IP Party shall provide the other Party
with the draft application as well as any material information in connection with such draft application (including copies of material correspondence from any external patent attorneys and agents pertaining thereto). 

 

	 	(ii)	 The other Party shall review the draft application and discuss any concerns in relation to the draft
application with the Lead IP Party. The Lead IP Party shall only be entitled to file any application for any Joint Patent Right after the relevant application has been approved in writing by the other Party (such approval not to be unreasonably
withheld or delayed). Any such filing shall be made in both Parties’ name, unless otherwise agreed between the Parties. 

  

	 	(iii)	 Following any filing of any application for any such Joint Patent Right, the Lead IP Party shall keep the other
Party informed of all material developments in relation to such Joint Patent Right, including any potential material correspondence from patent/intellectual property offices or any opposition or other claims of any Third Party with respect of such
Joint Patent Right. Any material submission by the Lead IP Party to any patent/intellectual property offices in relation to such Joint Patent Right shall require the other Party’s prior written consent (which shall not be unreasonably withheld
or delayed). 

  

	 	(iv)	 The Parties shall seek to act timely in their review and approval of any matter under this Section 5.5.3
in order to allow the Lead IP Party to comply with relevant filing deadlines or similar time limitations. 

  

	 	(v)	 Subject to subsection (vi) below, the Parties shall [***] associated with the filing and maintenance of
any application for a Joint Patent Right. 

  

	 	(vi)	 If a Party wishes to discontinue the prosecution and maintenance [***] of a Joint Patent Right (in one or more
countries), it shall provide reasonable prior written notice thereof to the other Party (which notice shall, to the extent 

  
 14|30 

	 	
possible, be given no later than [***] prior to the next deadline for any action that must be taken with respect to any such Joint Patent Right in the relevant patent office). In such event, at
the other Party’s election, the other Party may continue such prosecution and maintenance at its sole discretion and cost in such country(ies). In such event, the discontinuing Party shall execute in a timely manner and at the continuing
Party’s reasonable expense an assignment of such Joint Patent Right to the continuing Party (in such country or all countries, as applicable) and any additional documents as may be necessary to allow the continuing Party to prosecute and
maintain such Joint Patent Right. Any Joint Patent Right so assigned shall thereafter be owned solely by the continuing Party, shall no longer be considered jointly owned, and the discontinuing Party shall have a perpetual, non-exclusive, royalty-free, non-transferable, non-sub-licensable license to practice under
such Joint Patent Right in the applicable country or countries. [***] 

  

	 	5.6	 Inventor Compensation. Each Party shall be responsible for payment of any consideration which it is
required to pay to its employees or independent consultants or Subcontractors as compensation for the assignment of rights to any Foreground IP according to the legal provisions applicable in the relevant country and/or a contractual obligation.

  

	 	5.7	 Enforcement.  

 

	 	5.7.1	 Affimed shall have the sole right (but not the obligation) to enforce any Patent Rights covering its Background
IP and/or any Affimed Improvement. 

  

	 	5.7.2	 Artiva shall have the sole right (but not the obligation) to enforce any Patent Rights covering its Background
IP and/or any Artiva Improvement. 

  

	 	5.7.3	 If a Party becomes aware of any actual or suspected infringement or unauthorized use by a Third Party of any
Joint IP, then such Party shall promptly notify the other Party, through the Steering Committee, in writing of all the relevant facts and circumstances in connection with such infringement or unauthorized use known to that Party and shall provide
the other Party with all available evidence supporting such infringement or unauthorized use. 

  

	 	5.7.4	 The Steering Committee shall determine any required or desirable action to any such Third Party infringement of
Joint IP, which action shall be then be implemented by the Lead IP Party (Infringement Proceeding). [***] associated with any such joint Infringement Proceeding, unless otherwise agreed in writing. The Parties shall also share

  
 15|30 

	 	
[***] any damages, royalties, settlement fees or other consideration resulting from any such joint Infringement Proceedings, unless otherwise agreed in writing. 

 

	 	5.7.5	 The Lead IP Party shall keep the other Party informed of the status of any such joint Infringement Proceedings
and, upon request, shall (to the extent permitted under Applicable Law) provide the other Party, with copies of all documents filed in, and all material written communications between the parties relating to, such Infringement Proceeding. Upon
request of the Lead IP Party, the other Party shall give the Lead Party all reasonable assistance in any such Infringement Proceeding. 

  

	 	5.7.6	 No settlement shall be entered into by the Lead IP Party without the prior written consent of the other Party
(such consent not to be unreasonably withheld or delayed). 

  

	 	5.7.7	 All monies or other recoveries awarded to the Lead IP Party as part of any Infringement Proceeding or any
settlement thereof shall be [***] 

  

	 	5.7.8	 If the Parties do not agree to initiating such an Infringement Proceeding, [***] Neither Party shall enter into
any settlement of any enforcement action under this Section 5.7.8 without the prior written consent of the other Party, such consent not to be unreasonably withheld. 

 

	6.	 Confidentiality 

 

	 	6.1	 Confidentiality and Restricted Use. Each Party (Receiving Party) shall protect the
Confidential Information of the other Party (Disclosing Party) from unauthorized use or disclosure and use at least the same standard of care as it uses to protect its own Confidential Information and to make sure that its and its
Affiliates’ employees, agents, consultant and clinical investigators only make use of the Disclosing Party’s Confidential Information for the purposes expressly authorized or contemplated by this Agreement. 

 

	 	6.2	 Disclosure to Third Parties. Neither Party shall, except with the express prior written consent of the
Disclosing Party, disclose any Confidential Information of the Disclosing Party to any person or entity other than its and its Affiliates’ officers, directors, employees, agents, consultants, sublicensees and Subcontractors who need to know
such information for the purposes of this Agreement and who are bound by a written confidentiality agreement not less stringent than the terms of this Agreement or by professional rules of secrecy. 

 

	 	6.3	 Exceptions. The above confidentiality obligations shall not apply to information which, as can be
established by the Receiving Party, 

  
 16|30 

	 	a)	 was rightfully communicated to the Receiving Party from a Third Party who had the right to disclose such
information without restriction; 

  

	 	b)	 was already in the public domain or subsequently entered the public domain through no fault of the Receiving
Party and its Affiliates; or 

  

	 	c)	 was already known by the Receiving Party or its Affiliates before the effective date of this Agreement or
developed independently by the Receiving Party or its Affiliates without reference to or reliance upon Confidential Information provided by the Disclosing Party. 

 

	 	6.4	 Permitted Disclosures. Notwithstanding the provisions of Section 6.1, the Receiving Party may
disclose Confidential Information of the Disclosing Party as expressly permitted by this Agreement, or if and to the extent such disclosure is reasonably necessary in the following instances: 

 

	 	a)	 disclosure pursuant to any Applicable Law or legal, regulatory or stock exchange requirement, provided that the
Receiving Party shall wherever possible provide prior written notice of such disclosure to the Disclosing Party and take reasonable and lawful actions to avoid or minimize the degree of disclosure. The Parties agree that nothing in this
Section 6.4 is intended to require a Party to not comply with any Applicable Law; or 

  

	 	b)	 disclosure solely to the extent reasonably necessary in a patent application claiming Foreground IP made
hereunder in accordance with Section 5.5, to be filed with any patent office, provided that the Party filing the patent shall provide at least [***] prior written notice of such disclosure to the other Party, obtain the other Party’s prior
written consent, which shall not be unreasonably withheld or delayed, and take reasonable and lawful actions to avoid or minimize the degree of disclosure. 

  

	 	6.5	 Prior Confidentiality Agreement. As of the Effective Date, this Agreement terminates, supersedes and
replaces the Prior Confidentiality Agreement with respect to information disclosed thereunder. Nothing herein shall release either Party for any liability incurred under the Prior Confidentiality Agreement prior to the Effective Date.

  

	 	6.6	 Terms of the Agreement. Except as provided for by Section 6.8, Affimed and Artiva shall not disclose the
existence of nor any terms or conditions of this Agreement to any Third Party without the prior consent of the other Party, except as required by Applicable Law or to comply with rules of a securities exchange or regulatory authority, in which case
the Disclosing Party shall to the extent possible provide notice to the other Party and take reasonable and lawful actions to avoid or minimize the degree of such disclosures. Notwithstanding the foregoing, each Party may disclose the existence of
and terms and conditions of this Agreement, without such consent, to advisors, existing and potential investors, licensors, licensees, assignees and/or acquirers on a need to know basis under circumstances that reasonably ensure the confidentiality
thereof. 

  
 17|30 

	 	6.7	 Publications. Neither Party shall make any scientific publication or similar scientific disclosure in
relation to the Combination Product without the prior written consent of the other Party (which shall not be unreasonably withheld or delayed). Each Party shall submit copies of each such proposed publication or presentation to the other Party at
least [***] in advance of submitting such proposed publication or presentation to a publisher or other Third Party. Such other Party shall have the right to review, comment on and approve each such proposed publication or presentation for accuracy
and to ascertain whether such Party’s Confidential Information is being inappropriately utilized and/or released. The non-publishing Party shall have the right to remove any of its Confidential
Information prior to submission for publication or presentation. The publishing Party shall redact or otherwise modify the proposed publication or presentation to remove any such Confidential Information of the other Party and provide the final
manuscript of the publication or presentation to the non-publishing Party for release (such release not to be unreasonably withheld or delayed). If the non-publishing
Party fails to notify the publishing Party during the [***] period set forth above, the publishing Party may proceed with the proposed publication or presentation. At the request of the non-publishing Party,
any publication may be delayed up to [***] to enable the non-publishing Party to secure adequate intellectual property protection of its confidential information that would otherwise be affected by the
publication. 

  

	 	6.8	 Disclosures and Press Release. Neither Party may disclose the existence of this Agreement to a Third
Party, even under confidentiality, until the Parties agree on the timing of a disclosure. Furthermore, the Parties will also issue a joint press release regarding this Agreement and shall mutually agree on the timing and content of such press
release. Subject to any disclosure required by applicable law or administrative order, neither Party shall issue a press release or make any public disclosure regarding the existence and content of this Agreement without prior written approval from
the other Party. Once such a press release or other public disclosure has been made, the information contained therein will no longer be subject to the restrictions of Section 6.6. 

 

	7.	 Governance 

  

	 	7.1	 Alliance Managers. Each Party shall appoint a person to coordinate its part of the activities under this
Agreement (each, an Alliance Manager). The Alliance Managers shall be the primary contact between the Parties with respect to all activities performed under this Agreement and shall be responsible for overseeing the operation of the
collaboration. The Alliance Managers will meet in person or per telephone or video conference as necessary to fully comply with their responsibilities. They shall report to the Steering Committee. Either Party may change its Alliance Manager upon
written notice to the other Party. The Alliance Managers shall have no authority to amend or modify the terms and conditions of any Preclinical Assessment Plan or of this Agreement. 

 

	 	7.2	 Steering Committee. Within [***] following the Effective Date, the Parties shall establish a
steering committee (the Steering Committee). The Steering Committee shall initially consist of a total of [***] members. [***] of such members shall be appointed by Affimed, and [***] or more such 

  
 18|30 

	 	
members shall be appointed by Artiva. Each Steering Committee member shall have sufficient authority to ensure acceptance and execution of Steering Committee decisions within its organization.
Each Party may appoint substitutes or alternates for its Steering Committee members at any time by written notice to the other Party. The Parties may mutually agree to change the size of the Steering Committee at any time, provided that each Party
shall continue to have the right to appoint an equal number of members. 

  

	 	7.3	 Meetings. Meetings of the Steering Committee shall be scheduled from time to time by mutual agreement of
the Parties or upon request of one Party, but in no event less than once every [***] The meetings may be held in person, per telephone or video conference. The Parties shall alternate in hosting the Steering Committee meetings. The Alliance Manager
of the Party hosting any Steering Committee meeting shall attend the meeting and record the minutes of the meeting in writing. Such minutes shall be circulated to the other Party’s Alliance Manager no later than [***] following the meeting for
review, comment and approval of the other Party. If no comments are received within [***] of the receipt of the minutes by a Party, unless otherwise agreed, they shall be deemed to be approved by such Party. Furthermore, if the Parties are unable to
reach agreement on the minutes within [***] of the applicable meeting, the sections of the minutes that have been mutually agreed between the Parties by that date shall be deemed approved and, in addition, each Party shall record in the same
document its own version of those sections of the minutes on which the Parties were not able to agree. Each Party may invite other of its relevant employees or consultants to a Steering Committee meeting as
non-voting observers, provided that (i) such Party must provide the other Party with advance written notice identifying each such observer and such other Party has no reasonable objection to such
observers, and (ii) such Party shall ensure that such observers are bound by written obligations relating to confidentiality and intellectual property that are consistent with this Agreement. Each Party shall be responsible for all travel and
related costs and expenses for its members to the Steering Committee and other representatives to attend meetings of, and otherwise participate on, the Steering Committee. 

 

	 	7.4	 Responsibilities of the Steering Committee. The Steering Committee shall be responsible for directing,
coordinating and supervising the Preclinical Assessment activities of the Parties hereunder. In particular, the Steering Committee shall: 

  

	 	a)	 review and approve strategies for the Preclinical Assessments of any Combination Products;

  

	 	b)	 review and approve the Preclinical Assessment Plan and Budgets, including the allocation of work and
responsibilities between the Parties, and authorize necessary amendments thereto; 

  

	 	c)	 determine whether a Preclinical Assessment Plan has been completed with respect to each Development Candidate;

  

	 	d)	 monitor the conduct, progress and results of each Party’s activities under the Preclinical Assessment
Plans; 

  
 19|30 

	 	e)	 agree in advance, review and approve the Costs that the Parties are entitled to incur under the Preclinical
Assessment Plans; and 

  

	 	f)	 serve as the initial forum for the settlement of disputes or disagreements; 

 

	 	g)	 selection and designation of Collaboration Targets; 

 

	 	h)	 selecting the Lead IP Party for prosecution of Joint IP under Section 5.5.3. 

The Steering Committee shall have no authority to amend or modify the terms and conditions of this Agreement. 

 

	 	7.5	 Decisions of the Steering Committee. At least [***] appointed by each Party shall be present at or shall
otherwise participate in each Steering Committee meeting. Each Party has one vote in the decisions of the Steering Committee. Decisions of the Steering Committee shall be unanimous. If the members of the Steering Committee cannot agree on a
particular issue, such issue shall be escalated pursuant to Section 11.3. Other communications between or among any members of the Steering Committee outside of a Steering Committee meeting shall not be deemed to constitute a Steering Committee
decision unless incorporated in meeting minutes, nor shall any decision of the Steering Committee outside its authority be deemed binding on either Party. 

  

	8.	 Representations and Warranties 

 

	 	8.1	 Mutual Representations and Warranties. Each Party hereby represents and warrants to the other Party
that: 

  

	 	a)	 it is duly organized and validly existing under the laws of the jurisdiction of its incorporation, and it has
the legal right and authority to enter into this Agreement; 

  

	 	b)	 this Agreement has been duly executed by it and is legally binding upon it, enforceable in accordance with its
terms, and the execution, delivery and performance of this Agreement as well as the licenses granted hereunder do not conflict with any agreement, instrument or understanding, oral or written, to which such Party may be bound; 

 

	 	c)	 it has obtained or will obtain written agreements from each of its employees, consultants, and contractors who
perform activities under the Preclinical Assessment Plan pursuant to this Agreement, which agreements will obligate such persons to obligations of confidentiality and non-use and to assign Foreground IP in a
manner consistent with the provisions of this Agreement; and 

  

	 	d)	 it has not been debarred by any Regulatory Authority or is, to the best of its knowledge, the subject of any
debarment proceedings of any Regulatory Authority; 

  
 20|30 

	 	8.2	 Affimed Representations and Warranties. Affimed represents and warrants that as of the Effective Date:

  

	 	a)	 it has the right to grant the licenses granted herein; and 

 

	 	b)	 it Controls the Affimed Compounds. 

 

	 	8.3	 Artiva Representations and Warranties. Artiva represents and warrants that as of the Effective Date:

  

	 	a)	 it has the right to grant the licenses granted herein; and 

 

	 	b)	 it Controls the Artiva Cell Products. 

 

	 	8.4	 Mutual Covenants. 

 

	 	8.4.1	 In the course of conducting the Preclinical Assessment Plans hereunder, neither Party nor its Affiliates shall
use any employee or consultant who has been debarred by any Regulatory Authority, or, to such Party’s or its Affiliates’ knowledge, is the subject of debarment proceedings by a Regulatory Authority. Each Party shall notify the other Party
promptly upon becoming aware that any of its or its Affiliates’ employees or consultants has been debarred or is the subject of debarment proceedings by any Regulatory Authority.  

 

	 	8.4.2	 Each Party and its Affiliates shall comply in all material respects with all Applicable Laws (including all
anti-corruption and anti-bribery laws) in relation to the conduct of the Preclinical Assessment Plans and performance of its obligations under this Agreement. 

 

	 	8.5	 Disclaimers. The Parties acknowledge and agree that the Preclinical Assessments be conducted under this
Agreement are experimental in nature, and that neither Party can guarantee a successful outcome thereof. Except as expressly provided in this Agreement, the Know-how, Confidential Information and Intellectual
Property Rights provided by each Party are provided “as is” and except as otherwise expressly set forth herein, neither Party makes any representations or extends any warranties of any kind, either express or implied, to the other Party,
and each Party hereby disclaims all implied warranties, including warranties of merchantability, fitness for a particular purpose or non-infringement. 

 

	9.	 Indemnification / Limitation of Liability. 

 

	 	9.1	 Indemnification for Third Party Claims. 

 

	 	9.1.1	 Indemnification by Affimed. Affimed shall defend, indemnify and hold harmless Artiva, its
Affiliates, and its and their employees, directors, Subcontractors and agents from and against any loss, damage, reasonable costs and expenses (including reasonable attorneys’ fees and expenses) (collectively, Losses) incurred in
connection with any claim, proceeding, or investigation by a Third Party arising out or caused by (a) any negligence or willful misconduct of Affimed (or any of its Affiliates, 

  
 21|30 

	 	
or its and their employees, directors, Subcontractors or agents); or (b) any breach by Affimed of any of its representations and warranties or any other covenants or obligations of Affimed
under this Agreement, except to the extent such Losses have been caused by circumstances which are subject to the indemnification by Artiva to Affimed pursuant to Section 9.1.2. 

 

	 	9.1.2	 Indemnification by Artiva. Artiva shall defend, indemnify and hold harmless
Affimed, its Affiliates, and its and their employees, directors, Subcontractors and agents from and against all Losses incurred in connection with any claim, proceeding, or investigation by a Third Party arising out or caused by (a) any
negligence or willful misconduct of Artiva (or any of its Affiliates, or its and their employees, directors, Subcontractors or agents); or (b) any breach by Artiva of any of its representations and warranties or any other covenants or
obligations of Artiva under this Agreement, except to the extent such Losses have been caused by circumstances which are subject to the indemnification by Affimed to Artiva pursuant to Section 9.1.1. 

 

	 	9.1.3	 Procedure. The indemnified Party shall give the indemnifying Party prompt notice of any
such Third Party claim or lawsuit (including a copy thereof) served upon it (provided, however, that any failure or delay to notify shall not excuse any obligation of the indemnifying Party except to the extent the indemnifying Party is actually
prejudiced thereby) and shall fully cooperate with the indemnifying Party and its legal representatives in the investigation of any matter the subject of indemnification. The indemnifying Party shall have the exclusive ability to defend or settle
any such claim or lawsuit, provided that the indemnifying Party shall not enter into any settlement agreement that admits fault, wrongdoing or damages with a claimant without the prior written consent of the Party seeking indemnification, which
consent shall not be unreasonably withheld or delayed. The indemnified Party shall have the right to participate, at its own expense and with counsel of its choice, in the defense of any claim or suit that has been assumed by the indemnifying Party,
provided that the indemnifying Party shall have no obligations with respect to any claims resulting from the indemnified Party’s admission, settlement or other communication without the prior written consent of the indemnifying Party.

  

	 	9.2	 LIMITATION OF LIABILITY. IN NO EVENT SHALL EITHER PARTY (OR ANY OF ITS AFFILIATES OR
SUBCONTRACTORS) BE LIABLE TO THE OTHER PARTY, NOR SHALL ANY INDEMNIFIED PARTY HAVE THE RIGHT TO RECOVER, ANY SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR OTHER SIMILAR DAMAGES OR ANY PUNITIVE DAMAGES OR ANY LOST PROFIT, LOST SALE OR LOST
OPPORTUNITY DAMAGES (WHETHER SUCH CLAIMED DAMAGES ARE DIRECT OR INDIRECT), WHETHER ARISING DIRECTLY OR INDIRECTLY OUT OF (A) THE MANUFACTURE OR USE OF ANY PROPRIETARY COMPOUND SUPPLIED HEREUNDER OR (B) ANY BREACH OF OR FAILURE TO PERFORM
ANY OF THE PROVISIONS OF 

  
 22|30 

	 	
THIS AGREEMENT OR ANY REPRESENTATION, WARRANTY OR COVENANT CONTAINED IN OR MADE PURSUANT TO THIS AGREEMENT, EXCEPT THAT SUCH LIMITATION SHALL NOT APPLY TO DAMAGES PAID OR PAYABLE TO A THIRD PARTY
BY AN INDEMNIFIED PARTY FOR WHICH THE INDEMNIFIED PARTY IS ENTITLED TO INDEMNIFICATION HEREUNDER OR WITH RESPECT TO DAMAGES ARISING OUT OF OR RELATED TO A PARTY’S BREACH OF ITS OBLIGATIONS UNDER THIS AGREEMENT WITH RESPECT TO USE, DISCLOSURE,
LICENSE, ASSIGNMENT OR OTHER TRANSFER OF CONFIDENTIAL INFORMATION OR JOINT IP. 

  

	10.	 Term and Termination 

 

	 	10.1	 Term. This Agreement shall become effective on the Effective Date and shall continue until all
Preclinical Assessment Plans have been completed and any related Option Periods have expired, unless terminated earlier in accordance with the provisions of this Section 10 (the Term). 

 

	 	10.2	 Termination for Cause. Either Party may terminate this Agreement at any time by written notice to the
other Party with immediate effect if: 

  

	 	a)	 the other Party materially breaches any material provision of this Agreement and fails to cure such breach
within [***] following its receipt of written notice thereof from the terminating Party; provided, however, that in the event of a good faith dispute with respect to the existence of a material breach, this Agreement shall not be terminated unless
it is finally determined under Section 10.3 that this Agreement was materially breached, and, the breaching Party fails to cure such breach within [***] after such determination. Except as set forth in section 10.4, a delay of the timelines as
agreed in the Preclinical Assessment Plan (or as modified by the Steering Committee and memorialized in written JSC minutes) by [***] or more is considered a material breach of this Agreement. 

 

	 	b)	 the other Party becomes insolvent, is compelled to file bankruptcy or is determined otherwise imminently
subject to control by a bankruptcy trustee or its equivalent to the laws of the jurisdiction in which such Party is doing business. Notwithstanding the foregoing, the Parties intend for this Agreement and the licenses granted herein to remain in
full force and effect so long as the non-insolvent Party remains in material compliance with the terms and conditions hereof; 

 

	 	c)	 either Party determines to withdraw any applicable Regulatory Approval for its Proprietary Compound or to
discontinue development of its Proprietary Compound, for medical, scientific or legal reasons; or 

  

	 	d)	 any Regulatory Authority takes any action, or raises any objection, that prevents (i) the terminating
Party from supplying its Proprietary Compound for the purposes of this Agreement. 

  
 23|30 

	 	10.3	 Termination in the Event of a Change of Control. [***] 

 

	 	10.4	 Effect of Expiration and Termination 

 

	 	10.4.1	 The termination or expiration of this Agreement shall not affect the rights and obligations of the Parties
accruing prior to such termination or expiration nor preclude either Party from pursuing all rights and remedies it may have hereunder or under Applicable Law with respect to any breach of this Agreement. 

 

	 	10.4.2	 Upon termination or expiration of this Agreement for any reason, save as expressly provided herein, all rights
and obligations of the Parties and all licenses granted hereunder (and all sublicenses granted to such licenses by a Party hereunder) will immediately cease and terminate; provided that if a termination is not for this Agreement in its entirety,
then the scope of such termination shall be limited to the particular Combination Product terminated. 

  

	 	10.4.3	 In the event of termination or expiration of this Agreement, the Parties shall promptly return to one another
or destroy all Confidential Information of the other Party and all copies and embodiments thereof (except that the Receiving Party shall have the right to retain one copy in its confidential files for record keeping purposes, provided, however,
retention of electronic copies of Confidential Information maintained pursuant to regular electronic data archiving and record retention policies and practices that apply to its own general electronic files and information shall not be deemed to be
a violation of this Agreement so long as such electronic files are (a) maintained only on centralized storage servers (and not on personal computers or devices), (b) not accessible by any of its personnel (other than its information technology
specialists), and (c) are not otherwise accessed subsequently except with the written consent of the disclosing Party or as required by law or legal process) and other materials created under this Agreement that are in a Party’s or its
Affiliates’ or Subcontractors’ possession or control in respect of the Combination Products. 

  

	 	10.4.4	 Subject to Section 10.4.2 above, in the event that this Agreement is terminated, each Party in possession
of Proprietary Compound of the other Party shall, at such other Party’s sole discretion, promptly either return or destroy all such Proprietary Compound pursuant to the other Party’s instructions. If the other Party requests that the Party
in possession of such other Party’s Proprietary Compound destroys the Proprietary Compound, the Party in possession of such other Party’s Compound shall provide written certification of such destruction. 

  
 24|30 

	 	10.4.5	 Subject to Section 10.4.2 above, upon receipt by either Party of a termination notice of this Agreement,
the Parties shall agree in good faith on a wind-down plan for Preclinical Assessment studies in a reasonable manner that avoids incurring any additional expenditures or non-cancellable obligations.

  

	 	10.4.6	 The following Sections shall survive termination or expiration of this Agreement: 1, 3.6 (for a duration of the
longer of (i) [***] or (ii) as required by Applicable Law), 5.1, 5.2, 5.4, 5.5, 5.6, 5.7, 6, 8, 9, 10.3, 10.4, 10.5, and 11. 

  

	 	10.5	 Force Majeure. No Party (or any of its Affiliates) shall be held liable or responsible to the other
Party (or any of its Affiliates), or be deemed to have defaulted under or breached the Agreement, for failure or delay by such Party in fulfilling or performing any term of the Agreement when such failure or delay is caused by or results from causes
beyond the reasonable control of the affected Party (or any of its Affiliates), including fire, floods, embargoes, war, acts of war (whether war be declared or not), insurrections, riots, civil commotions, epidemics or pandemics, acts of God,
earthquakes, or omissions or delays in acting by any Governmental Authority (collectively, Events of Force Majeure); provided, however, that the affected Party shall promptly inform the other Party of the existence of such Event of
Force Majeure and shall use all commercially reasonable efforts to eliminate, cure or overcome any such Event of Force Majeure and to resume performance of its obligations promptly. Notwithstanding the foregoing, to the extent that an Event of Force
Majeure continues for a period in excess of [***], the affected Party shall promptly notify in writing the other Party of such continued Event of Force Majeure and within [***] of the other Party’s receipt of such notice, the Parties shall
negotiate in good faith either (i) a resolution of the Event of Force Majeure, if possible, (ii) an extension by mutual agreement of the time period to resolve, eliminate, cure or overcome such Event of Force Majeure, (iii) an
amendment of this Agreement to the extent reasonably possible, or (iv) an early termination of this Agreement. If a solution under (i) to (iv) has not been reached after [***] of the other Party’s receipt of such notice, then the
Party not affected shall be entitled to give notice to the affected Party to terminate this Agreement, specifying the date (which shall not be less than [***] after the date on which the notice of termination is given) on which termination will take
effect. Such a termination notice shall be irrevocable, except with the consent of both Parties, and upon termination the provisions of Section 10.3 shall apply. 

 

	11.	 General Provisions 

 

	 	11.1	 Notices. Any consent, notice or report required or permitted to be given or made under this Agreement by
one of the Parties to the other shall be in writing and addressed to such other Party at its address indicated below, or to such other address as the addressee shall have last furnished in writing to the addressor, and shall be effective upon
receipt by the addressee. 

  
 25|30 

 
			
	If to Affimed:	  	Affimed GmbH
		  	Attention: Chief Executive Officer
		  	Im Neuenheimer Feld 582
		  	69120 Heidelberg
		  	Germany
		
		  	With a copy to
		  	Affimed GmbH
		  	Attention: General Counsel
		  	Im Neuenheimer Feld 582
		  	69120 Heidelberg
		  	Germany
		
	If to Artiva:	  	Artiva Biotherapeutics, Inc.
		  	Attention: Chief Executive Officer
		  	4747 Executive Drive #1150
		  	San Diego, CA 92121
		  	USA
		  	With a copy to [***]

  

	 	11.2	 Applicable Law. This Agreement shall be governed by and construed in accordance with the laws of the
state of New York, USA, without regard to the conflicts of law principles thereof. 

  

	 	11.3	 Dispute Resolution. Any controversy or claim arising out of or relating to this Agreement, including any
such controversy or claim involving Affiliates of any Party (each, a Dispute) shall be resolved as set forth in this Section 11.3. 

  

	 	11.3.1	 Escalation. Either Party may deliver written notice of a Dispute to the other Party. Thereafter, the
Dispute will be discussed within the Steering Committee. In the event any Dispute remains unresolved by the discussions within the Steering Committee for more than [***] after the Dispute first being raised by either Party in writing to the other
Party, such Dispute shall be brought to the attention of the [***] of Affimed and the [***] of Artiva, who shall attempt to resolve the Dispute in good faith within additional [***] If, following this subsequent
[***]-day period, the Dispute remains unresolved, Section 11.3.2 shall apply. 

  

	 	11.3.2	 Dispute Resolution. Following the process set forth in Section 11.3.1, if the Dispute
remains unresolved, such Dispute shall be brought in the state courts and the Federal courts for New York, New York, and the parties hereby consent to the personal jurisdiction and exclusive venue of these courts. 

 

	 	11.4	 Assignment. Except as otherwise expressly provided under this Agreement, neither Party may assign or
otherwise transfer this Agreement or any right or obligation hereunder (whether voluntarily, by operation of law or otherwise), without the prior express written consent of the other Party; provided however,

  
 26|30 

	 	
that (i) either Party shall be permitted to effect such an assignment or transfer to any of its Affiliates without the consent of the other Party, provided that the assigning Party shall
remain liable and responsible to the non-assigning Party for the performance and observance of all such duties and obligations of such Affiliate, and (ii) in the event a Party is acquired or is to be
acquired by a Third Party by merger, acquisition, or the sale of substantially all of the assets of the relevant division of such Party, then such Party may effect such an assignment or transfer to such acquiring third party without the consent of
the other Party, provided that the other Party may terminate this Agreement pursuant to Section 10.3. The rights and obligations of the parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted
assigns of the Parties. Any purported assignment or transfer in violation of this Section 11.4 shall be null and void. 

  

	 	11.5	 Subcontracting. Each Party shall have the right to delegate any portion of its obligations hereunder as
follows: (a) to such Party’s Affiliates; (b) to the extent related to the manufacture and supply of such Party’s Proprietary Compound; and (c) upon approval of the Steering Committee, which shall not be unreasonably withheld
or delayed. Any and all Third Parties to whom a Party delegates any of its obligations hereunder are referred to as Subcontractors. Notwithstanding any delegation of its obligations hereunder, each Party shall remain solely and fully
liable for the performance of its Affiliates and Subcontractors to which such Party delegates the performance of its obligations under this Agreement. Each Party shall ensure that each of its Affiliates and Subcontractors performs such Party’s
obligations pursuant to the terms of this Agreement. Each Party shall use commercially reasonable efforts to obtain and maintain copies of documents relating to the obligations performed by such Affiliates and Subcontractors that are required to be
provided to the other Party under this Agreement. 

  

	 	11.6	 Construction. This Agreement will be fairly interpreted in accordance with its terms and without any
strict construction in favor of or against any Party. 

  

	 	11.7	 Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as
to be effective and valid under Applicable Law, but if any provision of this Agreement is held to be prohibited by or invalid under Applicable Law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without
invalidating the remainder of such provisions or the remaining provisions of this Agreement. 

  

	 	11.8	 Headings. The captions to the sections hereof are not a part of this Agreement, but are merely guides or
labels to assist in locating and reading the sections hereof. 

  

	 	11.9	 Independent Contractors. Each Party hereby acknowledges that the Parties shall be independent
contractors. Neither Party shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior consent of the other Party to do so.

  
 27|30 

	 	11.10	 Waiver. The waiver by a Party of any right hereunder, or of any failure to perform or breach by the
other Party hereunder, shall not be deemed a waiver of any other right hereunder or of any other breach or failure by the other Party hereunder whether of a similar nature or otherwise. 

 

	 	11.11	 Modification. This Agreement (including the attached Annexes) shall not be modified without the prior
written consent of each Party. In the event that the terms of any Annex are inconsistent with the terms of this Agreement, this Agreement shall control, unless otherwise explicitly agreed to in writing by the Parties. 

 

	 	11.12	 Entire Agreement. This Agreement (including the attached Annexes) contains the entire understanding of
the Parties with respect to the subject matter hereof. All other express or implied representations, agreements and understandings with respect to the subject matter hereof, either oral or written, heretofore made are expressly superseded by this
Agreement. 

  

	 	11.13	 Counterparts. This Agreement may be executed in counterparts, all of which together shall constitute one
and the same instrument. Signing and delivery of this Agreement may be evidenced by a email/facsimile/telecopier transmission of the signed signature page to the other Party. 

[End of Agreement – Signatures on the following page] 

  
 28|30 

 IN WITNESS WHEREOF, authorized representatives of the Parties have duly executed this Agreement as of
the Effective Date. 
  

					
	Affimed GmbH
		
	By:	 	   /s/ Dr. Adi Hoess

		 	    Name:	 	Dr. Adi Hoess
		 	    Title:	 	Chief Executive Officer
		 	    Date:	 	11/5/2020
		
	By:	 	   /s/ Dr. Wolfgang Fischer

		 	    Name:	 	Dr. Wolfgang Fischer
		 	    Title:	 	Chief Operations Officer
		 	    Date:	 	11/5/2020
	
	Artiva Biotherapeutics, Inc.
		
	By:	 	   /s/ Thomas J. Farrell

		 	    Name:	 	Thomas J. Farrell
		 	    Title:	 	President & CEO
		 	    Date:	 	11/5/2020

  
 29|30 

 Annex 1 

[***] 

  
 30|30

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}]]